WO2019161626A1 - Corannulene-incorporated aie nanodots with highly suppressed nonradiative decay for boosted cancer phototheranostics in vivo - Google Patents
Corannulene-incorporated aie nanodots with highly suppressed nonradiative decay for boosted cancer phototheranostics in vivo Download PDFInfo
- Publication number
- WO2019161626A1 WO2019161626A1 PCT/CN2018/091220 CN2018091220W WO2019161626A1 WO 2019161626 A1 WO2019161626 A1 WO 2019161626A1 CN 2018091220 W CN2018091220 W CN 2018091220W WO 2019161626 A1 WO2019161626 A1 WO 2019161626A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- theranostic agent
- corannulene
- compound
- group
- aie
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 123
- 201000011510 cancer Diseases 0.000 title claims abstract description 46
- 238000001727 in vivo Methods 0.000 title abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 239000002105 nanoparticle Substances 0.000 claims abstract description 33
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 24
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 17
- 230000002776 aggregation Effects 0.000 claims abstract description 15
- 238000004220 aggregation Methods 0.000 claims abstract description 15
- 238000010521 absorption reaction Methods 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 37
- 238000003384 imaging method Methods 0.000 claims description 36
- 238000005415 bioluminescence Methods 0.000 claims description 31
- 230000029918 bioluminescence Effects 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 29
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 29
- 239000007850 fluorescent dye Substances 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- 238000000799 fluorescence microscopy Methods 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 229910052740 iodine Inorganic materials 0.000 claims description 10
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 230000012010 growth Effects 0.000 claims description 8
- 230000001747 exhibiting effect Effects 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 238000001218 confocal laser scanning microscopy Methods 0.000 claims description 6
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 6
- 238000010253 intravenous injection Methods 0.000 claims description 6
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims description 6
- 230000004614 tumor growth Effects 0.000 claims description 5
- 229910020366 ClO 4 Inorganic materials 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 claims description 3
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 claims description 3
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 claims description 3
- 230000002147 killing effect Effects 0.000 claims description 2
- VXRUJZQPKRBJKH-UHFFFAOYSA-N corannulene Chemical compound C1=CC(C2=C34)=CC=C3C=CC3=C4C4=C2C1=CC=C4C=C3 VXRUJZQPKRBJKH-UHFFFAOYSA-N 0.000 abstract description 36
- 238000001356 surgical procedure Methods 0.000 abstract description 23
- 239000011159 matrix material Substances 0.000 abstract description 8
- 238000011275 oncology therapy Methods 0.000 abstract description 6
- 238000005538 encapsulation Methods 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 description 33
- -1 z'-butyl Chemical group 0.000 description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 238000007912 intraperitoneal administration Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 230000005284 excitation Effects 0.000 description 11
- 206010051676 Metastases to peritoneum Diseases 0.000 description 10
- 208000010918 peritoneal neoplasm Diseases 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 9
- 0 CC1=*CCC=C1 Chemical compound CC1=*CCC=C1 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 229940125782 compound 2 Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 238000003775 Density Functional Theory Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- PQBAWAQIRZIWIV-UHFFFAOYSA-N N-methylpyridinium Chemical compound C[N+]1=CC=CC=C1 PQBAWAQIRZIWIV-UHFFFAOYSA-N 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 210000003200 peritoneal cavity Anatomy 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002296 dynamic light scattering Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000002073 fluorescence micrograph Methods 0.000 description 4
- 230000005283 ground state Effects 0.000 description 4
- 238000004896 high resolution mass spectrometry Methods 0.000 description 4
- 238000002675 image-guided surgery Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000002428 photodynamic therapy Methods 0.000 description 4
- 238000005424 photoluminescence Methods 0.000 description 4
- 230000000171 quenching effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 239000012223 aqueous fraction Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical group C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000005281 excited state Effects 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 238000004770 highest occupied molecular orbital Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000004768 lowest unoccupied molecular orbital Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000011368 organic material Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 2
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101000965658 Homo sapiens U6 snRNA-associated Sm-like protein LSm7 Proteins 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 102100040951 U6 snRNA-associated Sm-like protein LSm7 Human genes 0.000 description 2
- 241000021375 Xenogenes Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000005841 biaryl group Chemical group 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- VSXUCKWEKLXHQJ-UHFFFAOYSA-N bis[2-(4-methoxyphenyl)pyridin-4-yl]methanone Chemical compound COC1=CC=C(C=C1)C1=NC=CC(=C1)C(=O)C1=CC(=NC=C1)C1=CC=C(C=C1)OC VSXUCKWEKLXHQJ-UHFFFAOYSA-N 0.000 description 2
- IAQRGUVFOMOMEM-UHFFFAOYSA-N but-2-ene Chemical compound CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000002800 charge carrier Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 125000003106 haloaryl group Chemical group 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000004776 molecular orbital Methods 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 238000000103 photoluminescence spectrum Methods 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000006862 quantum yield reaction Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- FGEUIMWNIGSQPB-UHFFFAOYSA-N (4-methoxyphenyl)-pyridin-4-ylmethanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CC=NC=C1 FGEUIMWNIGSQPB-UHFFFAOYSA-N 0.000 description 1
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 description 1
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- DNUYOWCKBJFOGS-UHFFFAOYSA-N 2-[[10-(2,2-dicarboxyethyl)anthracen-9-yl]methyl]propanedioic acid Chemical compound C1=CC=C2C(CC(C(=O)O)C(O)=O)=C(C=CC=C3)C3=C(CC(C(O)=O)C(O)=O)C2=C1 DNUYOWCKBJFOGS-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- MGNZXYYWBUKAII-UHFFFAOYSA-N C1C=CC=CC1 Chemical compound C1C=CC=CC1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- ZGAADFJPUHVVIN-UHFFFAOYSA-N CCC(CC1)C=CC1OC Chemical compound CCC(CC1)C=CC1OC ZGAADFJPUHVVIN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000010541 McMurry coupling reaction Methods 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- MKYQPGPNVYRMHI-UHFFFAOYSA-N Triphenylethylene Chemical compound C=1C=CC=CC=1C=C(C=1C=CC=CC=1)C1=CC=CC=C1 MKYQPGPNVYRMHI-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- XMIJDTGORVPYLW-UHFFFAOYSA-N [SiH2] Chemical compound [SiH2] XMIJDTGORVPYLW-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000000701 chemical imaging Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- XNMQEEKYCVKGBD-UHFFFAOYSA-N dimethylacetylene Natural products CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 1
- AASUFOVSZUIILF-UHFFFAOYSA-N diphenylmethanone;sodium Chemical compound [Na].C=1C=CC=CC=1C(=O)C1=CC=CC=C1 AASUFOVSZUIILF-UHFFFAOYSA-N 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- NZBSAAMEZYOGBA-UHFFFAOYSA-N luminogren Chemical compound C12=NC3=CC=CC=C3N2C(=O)C2=CC=CC3=CC=CC1=C23 NZBSAAMEZYOGBA-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- PGXWDLGWMQIXDT-UHFFFAOYSA-N methylsulfinylmethane;hydrate Chemical compound O.CS(C)=O PGXWDLGWMQIXDT-UHFFFAOYSA-N 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000005693 optoelectronics Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 125000003933 pentacenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC5=CC=CC=C5C=C4C=C3C=C12)* 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 238000001577 simple distillation Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000003075 superhydrophobic effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- UMHFSEWKWORSLP-UHFFFAOYSA-N thiophene 1,1-dioxide Chemical compound O=S1(=O)C=CC=C1 UMHFSEWKWORSLP-UHFFFAOYSA-N 0.000 description 1
- LWRYDHOHXNQTSK-UHFFFAOYSA-N thiophene oxide Chemical compound O=S1C=CC=C1 LWRYDHOHXNQTSK-UHFFFAOYSA-N 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0023—Di-or triarylmethane dye
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Definitions
- the present subject matter relates generally to a series of compounds with aggregation-induced emission characteristics and near infrared absorption and their applications in bioimaging and phototheranostics.
- NPs fluorescent nanoparticles
- PDT photodynamic therapy
- EPR enhanced permeability and retention
- the fluorescent NPs must have several qualities, including sufficiently high near-infrared (NIR) emission (> 650 nm) ; reactive oxygen species (ROS) generation efficiency of the fluorescent component within the NPs; strong resistance to photobleaching; negligible cytotoxicity and in vivo toxicity; and suitable NP size and surface chemistry, permitting prominent EPR effect.
- NIR near-infrared
- ROS reactive oxygen species
- organic fluorophore-doped NPs Compared with other extensively investigated fluorescent NPs, organic fluorophore-doped NPs hold the advantages of tunable photophysical properties, flexible structural tailoring, and good biocompatibility.
- ⁇ -conjugated fluorophores tend to aggregate within NPs.
- aggregation within NPs often causes significant quenching of light emission and ROS production, owing to intramolecular interactions, such as ⁇ - ⁇ stacking and other nonradiative decays, which tremendously limit their application as cancer phototheranostics.
- AIEgens Aggregation-induced emission luminogens
- AIEgens have recently emerged as an alternative fluorescent material to construct fluorescent NPs, which perfectly address the challenge of ACQ and exhibit low in vivo side toxicities.
- AIEgens are often non-emissive in solution due to the consumption of the excited state energy via non-radiative relaxation by intramolecular motion. Upon aggregation, such relaxation from the lowest excited singlet state (S 1 ) to the ground state (S 0 ) is largely restricted due to steric hindrance, leading to the energy of S 1 going through the fluorescence pathway to S 0 .
- This uncommon feature makes AIEgens ideal for fabrication of fluorescent NPs (also referred to as AIE dots) with ultrahigh brightness and photobleaching threshold. Prior studies, however, failed to reveal how to control and optimize the fluorescence and ROS generation ability of AIE dots.
- compositions including the present compounds can include a corannulene-modified polyethylene glycol encapsulation matrix.
- the compositions can be in nanoparticle form. Encapsulating the AIE compounds within a corannulene matrix provides intra-particle rigidity and restricts intramolecular rotation of the encapsulated AIE compound, which results in enhanced fluorescence and ROS generation capacity of the compositions in vivo. Accordingly, the compositions can be useful in NIR imaging-guided cancer surgery and photodynamic cancer therapy.
- the compounds have a backbone structural formula selected from the group consisting of:
- each R 1 , R 1 ′, R 1 ”and R 1 ” is independently selected from the group consisting of
- each R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 is independently selected from the group consisting of H, alkyl, unsaturated alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C n H 2n+1 , C 10 H 7 , C 12 H 9 , alkoxy, OC 6 H 5 , OC 10 H 7 and OC 12 H 9 , C n H 2n COOH, C n H 2n NCS, C n H 2n N 3 , C n H 2n NH 2 , C n H 2n SH, C n H 2n Cl, C n H 2n Br, C n H 2n I, N (C n H m ) 2 , and SC n H m ;
- n and m are each independently an integer from 0-10;
- A is a monovalent counter ion
- the compound is:
- the present subject matter relates to a fluorescent nanoparticle composition, comprising a fluorescent compound exhibiting aggregation induced emission properties and corannulene-modified polyethylene glycol, wherein the corannulene-modified polyethylene glycol encapsulates the fluorescent compound, and the fluorescent compound has a backbone structural formula selected from the group consisting of:
- each R 1 , R 1 ′, R 1 ”and R 1 ” is independently selected from the group consisting of
- each R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 is independently selected from the group consisting of H, alkyl, unsaturated alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C n H 2n+1 , C 10 H 7 , C 12 H 9 , alkoxy, OC 6 H 5 , OC 10 H 7 and OC 12 H 9 , C n H 2n COOH, C n H 2n NCS, C n H 2n N 3 , C n H 2n NH 2 , C n H 2n SH, C n H 2n Cl, C n H 2n Br, C n H 2n I, N (C n H m ) 2 , and SC n H m , ; and
- n and m are each independently an integer from 0-10;
- A is a monovalent counter ion selected from the group consisting of I - , Cl - , Br - , PF 6 - , ClO 4 - , BF 4 - , BPh 4 - , and CH 3 PhSO 3 - ;
- Fig. 1 (A) depicts PL spectra of TPP-TPA in DMSO-H 2 O mixtures with different water fractions (f w ) .
- Fig. 1 (B) depicts plot of the relative PL intensity (I/I 0 ) at 680 nm versus fw of the DMSO-H 2 O mixture of TPP-TPA. Excitation wavelength: 440 nm (insets show the fluorescent photos of TPP-TPA in DMSO solution and DMSO-H2O mixture with the f w of 99%taken under 365 nm UV lamp; concentration of TPP-TPA: 1 ⁇ 10 -5 M) .
- Fig. 1 (C) depicts molecular orbital amplitude plots of HOMO and LUMO for TPP-TPA in ground states based on density functional theory (DFT) calculation under the method of opt wB97XD/6-31g**.
- DFT density functional theory
- Fig. 2 depicts high-resolution mass spectrum of compound 2.
- Fig. 3 depicts 1 H NMR spectrum of compound 2 in CD 2 Cl 2 .
- Fig. 4 depicts 13 C NMR spectrum of compound 2 in CD 2 Cl 2 .
- Fig. 5 depicts high-resolution mass spectrum of TPP-TPA.
- Fig. 6 depicts 1 H NMR spectrum of TPP-TPA in CD 2 Cl 2 .
- Fig. 7 depicts 13 C NMR spectrum of TPP-TPA in CD 2 Cl 2 .
- Fig. 8 depicts UV-vis spectrum of TPP-TPA in DMSO solution (concentration of TPP-TPA: 1 ⁇ 10 -5 M) .
- Fig. 9 depicts PL spectra of TPP-TPA in DMSO/H 2 O mixtures with the water fractions (f w ) of 80%, 90%and 99% (excitation wavelength: 440 nm) .
- Fig. 10 depicts density functional theory (DFT) calculation for TPP-TPA based on the method of opt wB97XD/6-31g**: (A and B) (molecular orbital amplitude plots of HOMO (A) and LUMO (B) for TPP-TPA in the excited states) .
- DFT density functional theory
- Fig. 11 depicts scheme for the preparation of Cor-AIE dots and DSPE-AIE dots using nanoprecipitation method.
- Fig. 12 depicts UV-vis spectrum of Cor-AIE dots and DSPE-AIE dots in aqueous solution (concentration: 0.01 mg/mL) .
- Figs. 13 (A) and 13 (B) depict DLS analysis and Figs. 13 (C) and 13 (D) depict TEM images of Cor-AIE dots (A and C) and DSPE-AIE dots (B and D) , respectively.
- Fig. 14 (A) depicts PL and Fig. 14 (B) depicts fluorecence lifetime spectra of Cor-AIE dots and DSPE-AIE dots (excitation wavelength: 500 nm; inset shows the fluorescent photo of Cor-AIE dots taken under 365 nm UV lamp) .
- Fig. 14 (C) depicts absorption spectra and Fig.
- FIG. 14 (D) depicts decomposition rate of ABDA for Cor-AIE dots (Up) and DSPE-AIE dots (Down) under white light irradiation (60 mW/cm 2 , 400-1000 nm) , where A 0 and A are the absorbance at 378 nm before and after irradiation, respectively (concentrations of nanoparticles (Cor-AIE dots and DSPE-AIE dots) and ABDA are 0.01 mg/mL and 100 ⁇ M, respectively.
- FIGS. 14 (E) and 14 (F) depict Jablonski diagrams showing the non-radiative, radiative and intersystem crossing (ISC) processes for AIEgens in flexible (DSPE-AIE dots) and rigid (Cor-AIE dots) matrixes (S 0 : the ground state, S 1 : the lowest excited singlet state, T 1 : the lowest excited triplet state; k nr , k r and k ISC are the rate constants of the non-radiative relaxation, the radiative decay and the ISC process, respectively; FL: fluorescence) .
- ISC intersystem crossing
- Figs. 15 (A) – (E) relate to 1 H NMR titration experiment with corannulene gradually added into TPP-TPA solution;
- Fig. 15 (A) depicts structures of TPP-TPA and corannulene with featured protons labeled with H a , H b , H c , H d , and H e .
- Figs. 15 (A) depicts structures of TPP-TPA and corannulene with featured protons labeled with H a , H b , H c , H d , and H e .
- TPP-TPA the aromatic protons of 1-methylpyridinium (B and D) , the methyl protons in 1-methylpyridinium and anisole (E) ) and corannulene (C) , as indicated with the dotted lines and evaluated by the related values (concentrations of TPP-TPA was 1 ⁇ 10 -2 M and corannulene were 1 ⁇ 10 -2 M (1 : 1) , 2 ⁇ 10 -2 M (1 : 2) , and 6 ⁇ 10 -2 M (1 : 6) in CD 2 Cl 2 solution) .
- Fig. 16 (A) depicts theoretical positions between corannulene and TPP-TPA; and Fig. 16 (B) depicts optimized molecular geometries of S 0 , S 1 and T 1 states for TPP-TPA at M06-2X/6-31G (d) level in the absence and presence of corannulene.
- FIG. 17 (E) depicts change in fluorescent intensity at 525 nm of Cor-AIE dots, H 2 DCF-DA, and their mixture in PBS upon white light (36 mW) for different times; (excitation wavelength: 488 nm; concentrations of Cor-AIE dots and H 2 DCF-DA are 0.01 mg/mL and 1 ⁇ M, respectively) .
- Figs. 17 (F-I) exhibit merged bright-field and fluorescent images of HeLa cells stained with (F, G) H 2 DCF-DA (1 ⁇ M) only and (H, I) Cor-AIE dots (0.01 mg/mL) and H2DCF-DA (1 ⁇ M) for 30 min (F, H) before and (G, I) after exposure to white light for 2 min. Excitation wavelength: 488 nm.
- Fig. 18 (A) depicts bright field, fluorescence, bioluminescence, and H&E staining images of the tumor nodules on the surface of the intraperitoneal intestines.
- Fig. 18 (B) depicts bright field, fluorescence, bioluminescence, and H&E staining images of the tumor nodules on the surface of the peritoneum in peritoneal carcinomatosis-bearing mice after intravenous injection of Cor-AIE dots for 24 h.
- Fig. 19 (A) depicts representative fluorescence images before operation.
- Fig. 19 (B) depicts representative fluorescence images after operation under white light.
- Fig. 19 (C) depicts representative fluorescence images after re-operation with the aid of Cor-AIE dots image-guidance.
- Fig. 19 (D) depicts the extracted nodules from unguided groups and Cor-AIE dots guided groups examined with a fluorescence imaging system (Left) and a bioluminescence imaging system (Right) .
- Fig. 19 (E) depicts a histogram of nodule diameters extracted from unguided and Cor-AIE dots-guided groups.
- Fig. 20 depicts a Kaplan–Meier survival curve of tumor-free survival rate after surgery versus time (days) showing improved long-term tumor-free survival with Cor-AIE dots fluorescence image-guided surgery (blue) compared to sham surgery and standard surgery (red) without Cor-AIE dots fluorescence guidance.
- Fig. 21 (A) depicts the time-dependent bioluminescence imaging of the peritoneal carcinomatosis-bearing mice after intravenous injection of Saline, DSPE-AIE dots, and Cor-AIE dots.
- Fig. 21 (B) depicts the average bioluminescence intensities of intraperitoneal tumors on days 0, 1, 3, 5, and 9.
- Fig. 21 (C) depicts the curve of survival rate after different treatments (all of the experiment groups are “Saline” , “Cor-AIE dots” , “Light (L) ” , “DSPE-AIE dots + L” , and “Cor-AIE dots + L” .
- “L” is under the white light (0.4 W cm -2 ) for 10 min; concentrations of DSPE-AIE dots and Cor-AIE dots are 1 mg mL -1 based on TPP-TPA; volume of injection is 150 ⁇ L) .
- Fig. 22 depicts time-dependent bioluminescence imaging of the peritoneal carcinomatosis-bearing mice in the groups of “Light (L) ” and “Cor-AIE dots” ( “L” is under white light (0.4 W cm -2 ) for 10 min; concentrations of Cor-AIE dots are 1 mg mL -1 based on TPP-TPA; volume of injection is 150 ⁇ L) .
- compositions of the present teachings can also consist essentially of, or consist of, the recited components, and that the processes of the present teachings can also consist essentially of, or consist of, the recited process steps.
- ⁇ ex refers to excitation wavelength
- aggregation caused quenching or “ACQ” as used herein refers to the phenomenon wherein the aggregation of ⁇ -conjugated fluorophores significantly decreases the fluorescence intensity of the fluorophores.
- the aggregate formation is said to “quench” light emission of the fluorophores.
- AIE aggregation induced emission
- Emission intensity refers to the magnitude of fluorescence/phosphorescence normally obtained from a fluorescence spectrometer or fluorescence microscopy measurement
- fluorophore or “fluorogen” as used herein refers to a molecule which exhibits fluorescence
- luminogen or “luminophore” as used herein refers to a molecule which exhibits luminescence
- AIEgen as used herein refers to a molecule exhibiting AIE characteristics.
- halo or “halogen” refers to fluoro, chloro, bromo, and iodo.
- alkyl refers to a straight-chain or branched saturated hydrocarbon group.
- alkyl groups include methyl (Me) , ethyl (Et) , propyl (e.g., n-propyl and z'-propyl) , butyl (e.g., n-butyl, z'-butyl, sec-butyl, tert-butyl) , pentyl groups (e.g., n-pentyl, z'-pentyl, -pentyl) , hexyl groups, and the like.
- an alkyl group can have 1 to 40 carbon atoms (i.e., C1-40 alkyl group) , for example, 1-30 carbon atoms (i.e., C1-30 alkyl group) .
- an alkyl group can have 1 to 6 carbon atoms, and can be referred to as a “lower alkyl group” .
- lower alkyl groups include methyl, ethyl, propyl (e.g., n-propyl and z'-propyl) , and butyl groups (e.g., n-butyl, z'-butyl, sec-butyl, tert-butyl) .
- alkyl groups can be substituted as described herein.
- An alkyl group is generally not substituted with another alkyl group, an alkenyl group, or an alkynyl group.
- alkenyl refers to a straight-chain or branched alkyl group having one or more carbon-carbon double bonds.
- alkenyl groups include ethenyl, propenyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl groups, and the like.
- the one or more carbon-carbon double bonds can be internal (such as in 2-butene) or terminal (such as in 1-butene) .
- an alkenyl group can have 2 to 40 carbon atoms (i.e., C2-40 alkenyl group) , for example, 2 to 20 carbon atoms (i.e., C2-20 alkenyl group) .
- alkenyl groups can be substituted as described herein.
- An alkenyl group is generally not substituted with another alkenyl group, an alkyl group, or an alkynyl group.
- heteroatom refers to an atom of any element other than carbon or hydrogen and includes, for example, nitrogen, oxygen, silicon, sulfur, phosphorus, and selenium.
- aryl refers to an aromatic monocyclic hydrocarbon ring system or a polycyclic ring system in which two or more aromatic hydrocarbon rings are fused (i.e., having a bond in common with) together or at least one aromatic monocyclic hydrocarbon ring is fused to one or more cycloalkyl and/or cycloheteroalkyl rings.
- An aryl group can have 6 to 24 carbon atoms in its ring system (e.g., C6-24 aryl group) , which can include multiple fused rings.
- a polycyclic aryl group can have 8 to 24 carbon atoms. Any suitable ring position of the aryl group can be covalently linked to the defined chemical structure.
- aryl groups having only aromatic carbocyclic ring include phenyl, 1-naphthyl (bicyclic) , 2-naphthyl (bicyclic) , anthracenyl (tricyclic) , phenanthrenyl (tricyclic) , pentacenyl (pentacyclic) , and like groups.
- polycyclic ring systems in which at least one aromatic carbocyclic ring is fused to one or more cycloalkyl and/or cycloheteroalkyl rings include, among others, benzo derivatives of cyclopentane (i.e., an indanyl group, which is a 5, 6-bicyclic cycloalkyl/aromatic ring system) , cyclohexane (i.e., a tetrahydronaphthyl group, which is a 6, 6-bicyclic cycloalkyl/aromatic ring system) , imidazoline (i.e., a benzimidazolinyl group, which is a 5, 6-bicyclic cycloheteroalkyl/aromatic ring system) , and pyran (i.e., a chromenyl group, which is a 6, 6-bicyclic cycloheteroalkyl/aromatic ring system) .
- aryl groups include benzodioxanyl, benzodioxolyl, chromanyl, indolinyl groups, and the like.
- aryl groups can be substituted as described herein.
- an aryl group can have one or more halogen substituents, and can be referred to as a “haloaryl” group.
- Perhaloaryl groups i.e., aryl groups where all of the hydrogen atoms are replaced with halogen atoms (e.g., -C 6 F 5 ) , are included within the definition of “haloaryl” .
- an aryl group is substituted with another aryl group and can be referred to as a biaryl group. Each of the aryl groups in the biaryl group can be substituted as disclosed herein.
- heteroaryl refers to an aromatic monocyclic ring system containing at least one ring heteroatom selected from oxygen (O) , nitrogen (N) , sulfur (S) , silicon (Si) , and selenium (Se) or a polycyclic ring system where at least one of the rings present in the ring system is aromatic and contains at least one ring heteroatom.
- Polycyclic heteroaryl groups include those having two or more heteroaryl rings fused together, as well as those having at least one monocyclic heteroaryl ring fused to one or more aromatic carbocyclic rings, non-aromatic carbocyclic rings, and/or non-aromatic cycloheteroalkyl rings.
- a heteroaryl group as a whole, can have, for example, 5 to 24 ring atoms and contain 1-5 ring heteroatoms (i.e., 5-20 membered heteroaryl group) .
- the heteroaryl group can be attached to the defined chemical structure at any heteroatom or carbon atom that results in a stable structure. Generally, heteroaryl rings do not contain O-O, S-S, or S-0 bonds. However, one or more N or S atoms in a heteroaryl group can be oxidized (e.g., pyridine Noxide thiophene S-oxide, thiophene S, S-dioxide) .
- heteroaryl groups include, for example, the 5-or 6-membered monocyclic and 5-6 bicyclic ring systems shown below:
- T is O, S, NH, N-alkyl, N-aryl, N- (arylalkyl) (e.g., N-benzyl) , SiH2, SiH (alkyl) , Si (alkyl) 2, SiH (arylalkyl) , Si (arylalkyl) 2, or Si (alkyl) (arylalkyl) .
- heteroaryl rings examples include pyrrolyl, furyl, thienyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, isothiazolyl, thiazolyl, thiadiazolyl, isoxazolyl, oxazolyl, oxadiazolyl, indolyl, isoindolyl, benzofuryl, benzothienyl, quinolyl, 2-methylquinolyl, isoquinolyl, quinoxalyl, quinazolyl, benzotriazolyl, benzimidazolyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzoxadiazolyl, benzoxazolyl, cinnolinyl, lH-indazolyl, 2H-indazo
- heteroaryl groups include 4, 5, 6, 7-tetrahydroindolyl, tetrahydroquinolinyl, benzothienopyridinyl, benzofuropyridinyl groups, and the like.
- heteroaryl groups can be substituted as described herein.
- a "donor” material refers to an organic material, for example, an organic nanoparticle material, having holes as the majority current or charge carriers.
- an "acceptor" material refers to an organic material, for example, an organic nanoparticle material, having electrons as the majority current or charge carriers.
- a "theranostic agent” refers to an organic material, for example, an organic nanoparticle material, having both diagnostic and therapeutic capabilities.
- the present subject matter contemplates a fluorescent compound having aggregation-induced emission (AIE) characteristics and exhibiting near infrared absorption.
- the compound can have a rotor-rich skeleton and an inherent charge.
- the compound can be in nanoparticle form.
- compositions including the fluorescent compound and corannulene-modified polyethylene glycol encapsulating the fluorescent compound can be in nanoparticle form.
- the fluorescent compound can be encapsulated by the corannulene-modified polyethylene glycol using nanoprecipitation under ultrasonic conditions.
- Compositions including the nanoparticle form of the fluorescent compound and the corannulene-modified polyethylene glycol are also referred to herein as “theranostic agents” or “Cor-AIE dots” .
- Encapsulating the fluorescent compound in a corannulene encapsulation matrix can enhance the intra-particle microenvironment and thereby provide enhanced fluorescence and ROS generation capacity in vivo.
- the corannulene matrix can provide intra-particle rigidity and restrict intramolecular rotation of the encapsulated compound, leading to highly suppressed non-radiative decay.
- the absorbed energy can flow to both the fluorescence pathway and the intersystem crossing (ISC) process. Intersystem crossing (ISC) from S 1 to the lowest excited triplet state (T 1 ) can result from the small S 1 -T 1 energy gap, and result in ROS production via energy transfer (ET) from T 1 to ambient oxygen (O 2 ) .
- ISC intersystem crossing
- the present compounds and compositions can be beneficial in diagnostic and phototheranostic applications, particularly with respect to NIR imaging-guided cancer surgery and photodynamic cancer therapy.
- the compounds have a backbone structural formula selected from the group consisting of:
- each R 1 , R 1 ′, R 1 ”and R 1 ” is independently selected from the group consisting of
- each R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 is independently selected from the group consisting of H, alkyl, unsaturated alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C n H 2n+1 , C 10 H 7 , C 12 H 9 , alkoxy, OC 6 H 5 , OC 10 H 7 and OC 12 H 9 , C n H 2n COOH, C n H 2n NCS, C n H 2n N 3 , C n H 2n NH 2 , C n H 2n SH, C n H 2n Cl, C n H 2n Br, C n H 2n I, N (C n H m ) 2 , and SC n H m ;
- n and m are each independently an integer from 0-10;
- A is a monovalent counter ion
- the compound is:
- the present subject matter relates to a fluorescent nanoparticle composition, comprising a fluorescent compound exhibiting aggregation induced emission properties and corannulene-modified polyethylene glycol, the corannulene-modified polyethylene glycol encapsulating the fluorescent compound, the fluorescent compound having a backbone structural formula selected from the group consisting of:
- each R 1 , R 1 ′, R 1 ”and R 1 ” is independently selected from the group consisting of
- each R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 is independently selected from the group consisting of H, alkyl, unsaturated alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C n H 2n+1 , C 10 H 7 , C 12 H 9 , alkoxy, OC 6 H 5 , OC 10 H 7 and OC 12 H 9 , C n H 2n COOH, C n H 2n NCS, C n H 2n N 3 , C n H 2n NH 2 , C n H 2n SH, C n H 2n Cl, C n H 2n Br, C n H 2n I, N (C n H m ) 2 , and SC n H m , ;
- n and m are each independently an integer from 0-10;
- A is a monovalent counter ion selected from the group consisting of I - , Cl - , Br - , PF 6 - , ClO 4 - , BF 4 - , BPh 4 - , and CH 3 PhSO 3 - ;
- the fluorescent compound of the composition can be:
- the theranostic agents described herein can be beneficial in cancer diagnostic and phototheranostic applications, particularly with respect to NIR imaging-guided cancer surgery and photodynamic cancer therapy.
- Image-guided cancer surgery using NIR fluorescence has been verified to be feasible during clinical cancer surgery, and holds great promise for successful outcomes in cancer surgery.
- the theranostic agents described herein can be used as efficient NIR fluorescent probes that meet the necessary requirements of image-guided cancer surgery.
- compositions including TPP-TPA and lipid-PEG (DSPE-PEG: 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-N- [methoxy (polyethylene glycol) -2000] ) and compositions including corannulene-modified PEG (Cor-PEG) , respectively, afforded two types of AIE dots with different intra-particle rigid microenvironments.
- Corannulene is a polyaromatic hydrocarbon from a part of C 60 and is well-known in organic optoelectronics due to its uneven electron distribution, electron-negative core, and electron-positive periphery.
- Corannulene possesses a bowl shape with large curvature that inhibits bowl-to-bowl inversion at room temperature, owing to the large energy barrier of 11.5 kcal/mol. Hence, corannulene possesses a large dipole moment of 2.1D, superhydrophobicity, and hyper-rigidity. Corannulene typically has a chemical formula of C 20 H 10 . The molecule consists of a cyclopentane ring fused with 5 benzene rings, so another name for it is [5] circulene. Corannulene has a typical structure of:
- TPP-TPA-loaded DSPE-PEG nanodots DSPE-AIE dots
- Cor-AIE dots show 4.0-fold amplified fluorescence quantum yield and 5.4-fold enhanced ROS production.
- 1 H NMR titration and theoretical calculations essentially demonstrate that the corannulene provides intra-particle rigidity and strong interactions with TPP-TPA, which restrict intramolecular rotation of the encapsulated AIEgens, leading to highly suppressed nonradiative decay. The absorbed energy thus flows to both the fluorescence pathway and ISC process.
- the present subject matter relates to a method of killing cancer cells, which can include contacting the theranostic agent with a target cancer cell, imaging the target cancer cell while the theranostic agent contacts the target cancer cell, and subjecting the target cancer cell to near infrared light irradiation while the theranostic agent contacts the target cancer cell to kill the target cancer cell.
- the imaging method can be selected from fluorescence microscopy, bioluminescence imaging, and confocal laser scanning microscopy.
- the theranostic agent can be combined with a buffer solution prior to contacting the target cancer cell.
- the present subject matter relates to a method of locating a tumor site in a patient, which can include administering the theranostic agent to the patient, contacting a tumor site with the theranostic agent, and locating the tumor site using an imaging method after the tumor site is contacted with the theranostic agent.
- the theranostic agent can be administered by intravenous injection.
- the theranostic agent can be combined with a buffer solution prior to administering the theranostic agent to the patient.
- the imaging method can include at least one of fluorescence microscopy, bioluminescence imaging, and confocal laser scanning microscopy. Luciferin can be administered to the patient prior to use of bioluminescence imaging.
- the tumor site can be irradiated with near-infrared light radiation which, when combined with the present compounds, can stop or inhibit the growth of the tumor.
- the compounds can be administered to the patient six hours prior to imaging and treatment of the tumor.
- the present subject matter relates to a method of stopping or inhibiting tumor growth in a patient, which can include administering the theranostic agent to the patient; contacting a tumor site with the theranostic agent; locating the tumor site using an imaging method after the tumor site is contacted with the theranostic agent; and subjecting the tumor site to near-infrared light irradiation while the theranostic agent is present at the tumor site to stop or inhibit the growth of the tumor.
- Subjecting the tumor site to near-infrared light irradiation while the theranostic agent is present at the tumor site generates reactive oxygen species to stop or inhibit the growth of the tumor.
- the theranostic agent can be administered by intravenous injection.
- the theranostic agent can be combined with a buffer solution prior to administering the theranostic agent to the patient.
- the imaging method can include at least one of fluorescence microscopy, bioluminescence imaging, and confocal laser scanning microscopy. Luciferin can be administered to the patient prior to use of bioluminescence imaging.
- THF THF (Labscan) was purified by simple distillation from sodium benzophenone ketyl under nitrogen immediately before use.
- MEM Minimum essential medium
- DMEM Dulbecco’s modified eagle medium
- FBS fetal bovine serum
- PBS phosphate buffered saline
- HRMS High-resolution mass spectrometry
- luciferase-expressed 4T1 breast cancer cells and human HeLa cancer cells were cultured in the DMEM containing 10%FBS and antibiotics (100 units/mL penicillin and 100 g/mL streptomycin) in a 5%CO 2 humidity incubator at 37 °C.
- MDCK-II, U87 cells were cultured in the DMEM containing 10%FBS and antibiotics (100 units/mL penicillin and 100 g/mL streptomycin) in a 5%CO 2 humidity incubator at 37 °C.
- the excised tumors of the mice were fixed in 4%formalin, processed into paraffin, sectioned at 5 ⁇ m thickness, and stained with hematoxylin and eosin (H&E) .
- the slices were examined by a digital microscope (Leica QWin) .
- Cor-PEG or DSPE-PEG (1 mg) powder and TPP-TPA (0.2 mg) were completely dissolved in THF (1 mL) . After that, the THF solution was added into 9 mL Milli-Q water (18.2 MU) slowly under continuous ultrasound (125 W) . The mixed solution was further kept in ultrasound for another 1 minute, then the THF was removed by evaporation while stirring under N 2 at room temperature. Finally, the clear solution was obtained for use.
- TPP-TPA UV-vis absorption and photoluminescence (PL) spectra of TPP-TPA are reflected in Figs. 8 and 1A.
- TPP-TPA absorbs at 440 nm with the absorption tail extended to 600 nm in DMSO, covering most of visible light range.
- Such solution emits almost no light even when increasing the water fraction (f w ) in the DMSO-H 2 O mixture up to 50%, which can be ascribed to the active intramolecular rotation of the aryl rings (Fig. 1C) .
- the emission of TPP-TPA was enhanced dramatically when the f w was over 50%.
- FIG. 1B shows the plot of emission intensity at 680 nm against f w and the inset fluorescent photos of the red emission in the 99%aggregated solution compared to the negligible emission in DMSO.
- TPP-TPA exhibited typical AIE characteristics.
- the emission intensity slightly decreased after the f w exceeded 80%, which is mainly attributed to the serious twisted intramolecular charge transfer (TICT) effect in the polar solvent water.
- TPP-TPA exhibited typical AIE characteristics.
- the emission intensity slightly decreased after the f w exceeded 80%, which is mainly attributed to the serious twisted intramolecular charge transfer (TICT) effect in the polar solvent water.
- TCT serious twisted intramolecular charge transfer
- Such effect can be further supported by the emission red shift of 10 nm from 80%to 99% (Fig. 9) and can also be indicated by the typical electron distribution of HOMO and LUMO in both ground and excited states (Figs. 1C and Figs. 10A-10B)
- the Stokes shift for TPP-TPA was evaluated to be 220 nm, which is much larger than the small Stokes shifts of less than 50 nm of most commercial NIR fluorophores, avoiding the light contamination of excitation light and self-absorption of emission during biomedical imaging.
- TPP-TPA-loaded NPs were prepared by a nanoprecipitation method as shown in Fig. 11.
- TPP-TPA was formulated using corannulene-modified polyethylene glycol ( “Cor-PEG” ) having a bowl-shaped corannulene and 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol) -2000] ( “DSPE-PEG” ) with linear alkyl chain as the encapsulation matrix, respectively, obtaining Cor-AIE dots and DSPE-AIE dots, which possess similar absorption to TPP-TPA itself in aqueous media (Fig. 12) .
- Cor-AIE dots and DSPE-AIE dots were recorded by dynamic light scattering (DLS) with the values of 46.9 nm and 49.1 nm, respectively (Figs. 13A and 13B) .
- TEM was further used to confirm these nanoparticles bearing the spherical shape (Figs. 13C and 13D) .
- Cor-AIE dots exhibited stronger emission with the quantum yield of 26.8%, which is four times larger than 6.7%for DSPE-AIE dots.
- the average fluorescence lifetime of Cor-AIE dots was measured to be 4.34 ns, which is about four times that of DSPE-AIE dots.
- FRET fluorescence resonance energy transfer
- DFT Density functional theory
- the bowl-shaped corannulene possesses a super-hydrophobic skeleton and an ultra-rigid curvature compared with the flexible alkyl-chained DSPE, and hence constructs a more confined microenvironment in aqueous solution.
- Corannulene bears a large dipole moment and the bottom of the corannulene bowl is electronegative with the periphery being electropositive, which attracts inherent positively-charged TPP-TPA by dipole-dipole and electrostatic interactions.
- Cor-AIE dots can also provide a more isolated hydrophobic environment to reduce the polar-solvent disruption (such as TICT) for TPP-TPA, bringing about further enhancement of emission efficiency and ROS production. Indeed, the reduced TICT effect in Cor-AIE dots was reflected by the slight blue shift of about 10 nm in the emission spectrum compared to DSPE-AIE dots (Fig. 14A) .
- TICT polar-solvent disruption
- Cor-AIE dots Due to the excellent NIR emission output and ROS production, the utility and strength of Cor-AIE dots in cancer phototheranostics were investigated. After it was demonstrated that Cor-AIE dots could be internalized in cancer cells and generate ROS within cells effectively (Figs. 17A-17I) , in vivo studies were carried out using a peritoneal carcinomatosis-bearing mouse model, which was established by intraperitoneal inoculation of murine 4T1 cancer cells, as described below. All animal studies were performed in compliance with the guidelines set by Tianjin Committee of Use and Care of Laboratory Animals and the overall project protocols were approved by the Animal Ethics Committee of Nankai University. All the mice were obtained from Laboratory Animal Center of the Academy of Military Medical Sciences (Beijing, China) .
- a total of 300,000 luciferase-expressed 4T1 cancer cells in 0.1 mL of PBS buffer were intraperitoneally injected into the Balb/c mice. After about 5 days, small tumor nodules were formed and scattered in the mouse peritoneal cavity, which could be detected by bioluminescence imaging upon injection of a solution of D-luciferin (150 mg/kg) .
- D-luciferin 150 mg/kg
- the in vivo inoculated 4T1 cancer cells express luciferase. As such, the living cancer cells emitted bioluminescence when the tumor-bearing mice were administered with the substrate of luciferase (D-luciferin) , allowing for precise tracking of the tumor nodules in the mouse peritoneal cavity.
- Cor-AIE dots (1 mg mL -1 based on TPP-TPA) was intravenously injected into the peritoneal carcinomatosis-bearing mice.
- the mice were anesthetized.
- the abdominal cavity of the mice was opened, followed by bioluminescence and fluorescence imaging during surgery.
- Bioluminescence imaging was performed using the Xenogen Lumina II system post intraperitoneal injection of D-luciferin (150 mg/kg) into the mice.
- the bioluminescence signals were quantified in units of maximum photons per second per square centimeter per steridian. Fluorescence imaging was carried out using a Maestro EX in vivo fluorescence imaging system (CRi, Inc.; excitation: 455 nm, spectral imaging from 500 nm to 900 nm) .
- Cor-AIE dots possess remarkable EPR effect, permitting high tumor uptake via passive targeting and thus leading to visualization of intraperitoneal tumor nodules and their boundaries in a specific and high-contrast manner.
- the fluorescence intensity ratios of tumor to normal tissues achieved by Cor-AIE dots are significantly higher than those of many reported NIR fluorescent probes including methylene blue and indocyanine green.
- the Cor-AIE dots can distinctly delineate the tumor nodules with sizes ⁇ 1 mm in the peritoneal cavity (indicated by the red arrows in Fig. 18) , revealing that Cor-AIE dots are efficacious in sharply visualizing submillimeter tumors due to their highly boosted NIR emission.
- Cor-AIE dots can serve as an extremely effective NIR fluorescent probe to precisely visualize tumors and their boundaries against normal tissues, its application in guidance for surgical tumor removal was studied. To this end, a surgeon from Tianjin First Central Hospital (Tianjin, China) was invited to conduct the operation. 150 ⁇ L of Cor-AIE dots (1 mg mL -1 based on TPP-TPA) was injected into the peritoneal carcinomatosis-bearing mice via the tail vein. After 24 h, tumor resection surgery was first performed by a surgeon from Tianjin First Central Hospital (Tianjin, China) without imaging guidance (unguided) . This was followed by a second surgery on the same mice by the guidance of Cor-AIE dots fluorescence. The excised tumor nodules were analyzed by both fluorescence imaging and bioluminescence imaging. The tumor sizes resected from the first and second surgery were also quantified.
- Figs. 19A and 19B when the surgeon was blinded to the NIR fluorescence imaging by Cor-AIE dots, he removed many intraperitoneal tumors with relatively large diameters (> 1 mm) . However, after the unguided surgery, there were a number of residual tumor nodules remaining in the peritoneal cavity indicated by Cor-AIE dots, which are mainly the ones with diameters ⁇ 1 mm (Fig. 19B) . The surgeon then performed a second operation under the guidance of Cor-AIE dots fluorescence, which achieved almost complete removal of the remaining small tumors (Figs. 19C-E) , confirmed by the negligible intraperitoneal bioluminescence signal.
- surgeons in practice cannot perform tumor-removal operations after opening their patients’abdomen because there are so many small tumors that are difficult to excise manually. As a result, surgeons are forced to close the abdominal wall and choose a treatment strategy other than surgery.
- Cor-AIE dots (1 mg mL -1 based on TPP-TPA; 150 ⁇ L) were intravenously injected into the mice in "Cor-AIE dots" and "Cor-AIE dots + L” groups.
- day 1 the mouse abdomen was opened for each mouse in these 2 groups.
- the whole peritoneal cavity was irradiated with white light (0.4 W cm -2 ) for 10 min, followed by closure of the abdomen, utilizing surgical sutures.
- mice in "Cor-AIE dots” group the mouse abdomen was subsequently closed without white light irradiation.
- DSPE-AIE dots + L DSPE-AIE dots (1 mg mL -1 based on TPP-TPA; 150 ⁇ L) were administered to the mice via the tail vein on day 0, followed by the same treatment as that for the mice in "Cor-AIE dots + L” group on day 1.
- saline saline was intravenously injected into the mice on day 0, followed by the same treatment as that for the mice in "Cor-AIE dots” group on day 1.
- Light the mice were untreated on day 0, but on day 1, the mice were treated following the same procedure as that for "Cor-AIE dots + L" group.
- the tumor size and growth were monitored during a 9-day study duration through bioluminescence imaging with the Xenogen Lumina II system post intraperitoneal injection of D-luciferin (150mg/kg) into the mice. The survival rates were also examined throughout the study.
- Fig. 21A and Fig. 22 exhibit time-dependent bioluminescence imaging of the tumor-bearing mice in each group. It was apparent that tumors with intense bioluminescence signal exist in the abdomen of mice before different treatments on day 0. Dramatically, after receiving the treatment of “Cor-AIE dots + L” , the intraperitoneal tumor growth of mice was considerably suppressed, as evidenced by the similar average bioluminescence intensity of intraperitoneal tumors on day 9 to that on day 0 (Fig. 21B) . As controls, both the treatments of “Cor-AIE dots” and “Light (L) ” failed to slow down the growth of intraperitoneal tumors, compared with that of “Saline” (Fig. 22 and Fig.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Nanotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present subject matter relates to fluorescent compounds that have aggregation-induced emission (AIE) characteristics and exhibit near infrared absorption. Compositions including the present compounds can include a corannulene-modified polyethylene glycol encapsulation matrix. The compositions can be in nanoparticle form. Encapsulating the AIE compounds within a corannulene matrix provides intraparticle rigidity and restricts intramolecular rotation of the encapsulated AIE compound, which results in enhanced fluorescence and ROS generation capacity of the compositions in vivo. Accordingly, the compositions can be useful in NIR imaging-guided cancer surgery and photodynamic cancer therapy.
Description
CROSS-REFERENCE
The present application claims priority to provisional United States Patent Application No. 62/710,470, filed February 21, 2018, which was filed by the inventors hereof and is incorporated herein by reference in its entirety.
The present subject matter relates generally to a series of compounds with aggregation-induced emission characteristics and near infrared absorption and their applications in bioimaging and phototheranostics.
Optical agents for cancer phototheranostics allow for real-time molecular diagnosis and concurrent light-triggered treatment. Among various phototheranostic agents, fluorescent nanoparticles (NPs) are particularly desirable due to their associated high sensitivity and temporal resolution of fluorescence imaging, on-demand and in situ signature of photodynamic therapy (PDT) , as well as unique enhanced permeability and retention (EPR) effects. To meet the requirements of ideal cancer phototheranostics, the fluorescent NPs must have several qualities, including sufficiently high near-infrared (NIR) emission (> 650 nm) ; reactive oxygen species (ROS) generation efficiency of the fluorescent component within the NPs; strong resistance to photobleaching; negligible cytotoxicity and in vivo toxicity; and suitable NP size and surface chemistry, permitting prominent EPR effect.
Compared with other extensively investigated fluorescent NPs, organic fluorophore-doped NPs hold the advantages of tunable photophysical properties, flexible structural tailoring, and good biocompatibility. However, π-conjugated fluorophores tend to aggregate within NPs. For conventional small-molecule fluorescent dyes with planar molecular structures, such aggregation within NPs often causes significant quenching of light emission and ROS production, owing to intramolecular interactions, such as π-π stacking and other nonradiative decays, which tremendously limit their application as cancer phototheranostics. Much effort has been devoted to overcome the aggregation-caused quenching (ACQ) effect within fluorescent NPs through the introduction of bulky side groups and hydrophobic counterions into fluorophores. Apparently, these prior efforts have not produced the desired output due to difficulties experienced in blocking the strong π-π stacking.
Aggregation-induced emission luminogens (AIEgens) have recently emerged as an alternative fluorescent material to construct fluorescent NPs, which perfectly address the challenge of ACQ and exhibit low in vivo side toxicities. AIEgens are often non-emissive in solution due to the consumption of the excited state energy via non-radiative relaxation by intramolecular motion. Upon aggregation, such relaxation from the lowest excited singlet state (S
1) to the ground state (S
0) is largely restricted due to steric hindrance, leading to the energy of S
1 going through the fluorescence pathway to S
0. This uncommon feature makes AIEgens ideal for fabrication of fluorescent NPs (also referred to as AIE dots) with ultrahigh brightness and photobleaching threshold. Prior studies, however, failed to reveal how to control and optimize the fluorescence and ROS generation ability of AIE dots.
Accordingly, advanced fluorescent NPs with both high fluorescence and ROS generation capacity for use as cancer phototheranostics are highly desirable.
SUMMARY
The present subject matter relates to fluorescent compounds that have aggregation-induced emission (AIE) characteristics and exhibit near infrared absorption. Compositions including the present compounds can include a corannulene-modified polyethylene glycol encapsulation matrix. The compositions can be in nanoparticle form. Encapsulating the AIE compounds within a corannulene matrix provides intra-particle rigidity and restricts intramolecular rotation of the encapsulated AIE compound, which results in enhanced fluorescence and ROS generation capacity of the compositions in vivo. Accordingly, the compositions can be useful in NIR imaging-guided cancer surgery and photodynamic cancer therapy.
In an embodiment, the compounds have a backbone structural formula selected from the group consisting of:
wherein each R
1, R
1′, R
1”and R
1”’is independently selected from the group consisting of
wherein each R
2, R
3, R
4, R
5, R
6, and R
7 is independently selected from the group consisting of H, alkyl, unsaturated alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C
nH
2n+1, C
10H
7, C
12H
9, alkoxy, OC
6H
5, OC
10H
7 and OC
12H
9, C
nH
2nCOOH, C
nH
2nNCS, C
nH
2nN
3, C
nH
2nNH
2, C
nH
2nSH, C
nH
2nCl, C
nH
2nBr, C
nH
2nI, N (C
nH
m)
2, and SC
nH
m;
wherein n and m are each independently an integer from 0-10;
wherein A is a monovalent counter ion; and
wherein the monovalent counter ion is always present in the compound.
In a further embodiment, the compound is:
In yet another embodiment, the present subject matter relates to a fluorescent nanoparticle composition, comprising a fluorescent compound exhibiting aggregation induced emission properties and corannulene-modified polyethylene glycol, wherein the corannulene-modified polyethylene glycol encapsulates the fluorescent compound, and the fluorescent compound has a backbone structural formula selected from the group consisting of:
wherein each R
1, R
1′, R
1”and R
1”’is independently selected from the group consisting of
wherein each R
2, R
3, R
4, R
5, R
6, and R
7 is independently selected from the group consisting of H, alkyl, unsaturated alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C
nH
2n+1, C
10H
7, C
12H
9, alkoxy, OC
6H
5, OC
10H
7 and OC
12H
9, C
nH
2nCOOH, C
nH
2nNCS, C
nH
2nN
3, C
nH
2nNH
2, C
nH
2nSH, C
nH
2nCl, C
nH
2nBr, C
nH
2nI, N (C
nH
m)
2, and SC
nH
m, ; and
wherein n and m are each independently an integer from 0-10;
wherein A is a monovalent counter ion selected from the group consisting of I
-, Cl
-, Br
-, PF
6
-, ClO
4
-, BF
4
-, BPh
4
-, and CH
3PhSO
3
-; and
wherein the monovalent counter ion is always present in the compound.
BRIEF DESCRIPTION OF DRAWINGS
Various embodiments will now be described in detail with reference to the accompanying drawings.
Fig. 1 (A) depicts PL spectra of TPP-TPA in DMSO-H
2O mixtures with different water fractions (f
w) . Fig. 1 (B) depicts plot of the relative PL intensity (I/I
0) at 680 nm versus fw of the DMSO-H
2O mixture of TPP-TPA. Excitation wavelength: 440 nm (insets show the fluorescent photos of TPP-TPA in DMSO solution and DMSO-H2O mixture with the f
w of 99%taken under 365 nm UV lamp; concentration of TPP-TPA: 1 × 10
-5M) . Fig. 1 (C) depicts molecular orbital amplitude plots of HOMO and LUMO for TPP-TPA in ground states based on density functional theory (DFT) calculation under the method of opt wB97XD/6-31g**.
Fig. 2 depicts high-resolution mass spectrum of compound 2.
Fig. 3 depicts
1H NMR spectrum of compound 2 in CD
2Cl
2.
Fig. 4 depicts
13C NMR spectrum of compound 2 in CD
2Cl
2.
Fig. 5 depicts high-resolution mass spectrum of TPP-TPA.
Fig. 6 depicts
1H NMR spectrum of TPP-TPA in CD
2Cl
2.
Fig. 7 depicts
13C NMR spectrum of TPP-TPA in CD
2Cl
2.
Fig. 8 depicts UV-vis spectrum of TPP-TPA in DMSO solution (concentration of TPP-TPA: 1 × 10
-5 M) .
Fig. 9 depicts PL spectra of TPP-TPA in DMSO/H
2O mixtures with the water fractions (f
w) of 80%, 90%and 99% (excitation wavelength: 440 nm) .
Fig. 10 depicts density functional theory (DFT) calculation for TPP-TPA based on the method of opt wB97XD/6-31g**: (A and B) (molecular orbital amplitude plots of HOMO (A) and LUMO (B) for TPP-TPA in the excited states) .
Fig. 11 depicts scheme for the preparation of Cor-AIE dots and DSPE-AIE dots using nanoprecipitation method.
Fig. 12 depicts UV-vis spectrum of Cor-AIE dots and DSPE-AIE dots in aqueous solution (concentration: 0.01 mg/mL) .
Figs. 13 (A) and 13 (B) depict DLS analysis and Figs. 13 (C) and 13 (D) depict TEM images of Cor-AIE dots (A and C) and DSPE-AIE dots (B and D) , respectively.
Fig. 14 (A) depicts PL and Fig. 14 (B) depicts fluorecence lifetime spectra of Cor-AIE dots and DSPE-AIE dots (excitation wavelength: 500 nm; inset shows the fluorescent photo of Cor-AIE dots taken under 365 nm UV lamp) . Fig. 14 (C) depicts absorption spectra and Fig. 14 (D) depicts decomposition rate of ABDA for Cor-AIE dots (Up) and DSPE-AIE dots (Down) under white light irradiation (60 mW/cm
2, 400-1000 nm) , where A
0 and A are the absorbance at 378 nm before and after irradiation, respectively (concentrations of nanoparticles (Cor-AIE dots and DSPE-AIE dots) and ABDA are 0.01 mg/mL and 100 μM, respectively. Figs. 14 (E) and 14 (F) depict Jablonski diagrams showing the non-radiative, radiative and intersystem crossing (ISC) processes for AIEgens in flexible (DSPE-AIE dots) and rigid (Cor-AIE dots) matrixes (S
0: the ground state, S
1: the lowest excited singlet state, T
1: the lowest excited triplet state; k
nr, k
r and k
ISC are the rate constants of the non-radiative relaxation, the radiative decay and the ISC process, respectively; FL: fluorescence) .
Figs. 15 (A) – (E) relate to
1H NMR titration experiment with corannulene gradually added into TPP-TPA solution; Fig. 15 (A) depicts structures of TPP-TPA and corannulene with featured protons labeled with H
a, H
b, H
c, H
d, and H
e. Figs. 15 (B) - (E) depict changes of chemical shifts for TPP-TPA (the aromatic protons of 1-methylpyridinium (B and D) , the methyl protons in 1-methylpyridinium and anisole (E) ) and corannulene (C) , as indicated with the dotted lines and evaluated by the related values (concentrations of TPP-TPA was 1 × 10
-2 M and corannulene were 1 × 10
-2 M (1 : 1) , 2 × 10
-2 M (1 : 2) , and 6 × 10
-2 M (1 : 6) in CD
2Cl
2 solution) .
Fig. 16 (A) depicts theoretical positions between corannulene and TPP-TPA; and Fig. 16 (B) depicts optimized molecular geometries of S
0, S
1 and T
1 states for TPP-TPA at M06-2X/6-31G (d) level in the absence and presence of corannulene.
Figs. 17 (A) – (D) depict confocal images of HeLa cells after incubation with Cor-AIE dots for 1 h at 37 ℃ (red, λ
ex = 560 nm, λ
em = 570–720 nm) (the nucleus was stained by Hoechst 33342 (blue, λ
ex = 405 nm, λ
em = 430–470 nm) (concentration: 1×10
-5 M; release of ROS monitored by H
2DCF-DA) . Fig. 17 (E) depicts change in fluorescent intensity at 525 nm of Cor-AIE dots, H
2DCF-DA, and their mixture in PBS upon white light (36 mW) for different times; (excitation wavelength: 488 nm; concentrations of Cor-AIE dots and H
2DCF-DA are 0.01 mg/mL and 1 μM, respectively) . Figs. 17 (F-I) exhibit merged bright-field and fluorescent images of HeLa cells stained with (F, G) H
2DCF-DA (1 μM) only and (H, I) Cor-AIE dots (0.01 mg/mL) and H2DCF-DA (1 μM) for 30 min (F, H) before and (G, I) after exposure to white light for 2 min. Excitation wavelength: 488 nm.
Fig. 18 (A) depicts bright field, fluorescence, bioluminescence, and H&E staining images of the tumor nodules on the surface of the intraperitoneal intestines. Fig. 18 (B) depicts bright field, fluorescence, bioluminescence, and H&E staining images of the tumor nodules on the surface of the peritoneum in peritoneal carcinomatosis-bearing mice after intravenous injection of Cor-AIE dots for 24 h.
Fig. 19 (A) depicts representative fluorescence images before operation. Fig. 19 (B) depicts representative fluorescence images after operation under white light. Fig. 19 (C) depicts representative fluorescence images after re-operation with the aid of Cor-AIE dots image-guidance. Fig. 19 (D) depicts the extracted nodules from unguided groups and Cor-AIE dots guided groups examined with a fluorescence imaging system (Left) and a bioluminescence imaging system (Right) . Fig. 19 (E) depicts a histogram of nodule diameters extracted from unguided and Cor-AIE dots-guided groups.
Fig. 20 depicts a Kaplan–Meier survival curve of tumor-free survival rate after surgery versus time (days) showing improved long-term tumor-free survival with Cor-AIE dots fluorescence image-guided surgery (blue) compared to sham surgery and standard surgery (red) without Cor-AIE dots fluorescence guidance.
Fig. 21 (A) depicts the time-dependent bioluminescence imaging of the peritoneal carcinomatosis-bearing mice after intravenous injection of Saline, DSPE-AIE dots, and Cor-AIE dots. Fig. 21 (B) depicts the average bioluminescence intensities of intraperitoneal tumors on days 0, 1, 3, 5, and 9. Fig. 21 (C) depicts the curve of survival rate after different treatments (all of the experiment groups are “Saline” , “Cor-AIE dots” , “Light (L) ” , “DSPE-AIE dots + L” , and “Cor-AIE dots + L” . “L” is under the white light (0.4 W cm
-2) for 10 min; concentrations of DSPE-AIE dots and Cor-AIE dots are 1 mg mL
-1 based on TPP-TPA; volume of injection is 150 μL) .
Fig. 22 depicts time-dependent bioluminescence imaging of the peritoneal carcinomatosis-bearing mice in the groups of “Light (L) ” and “Cor-AIE dots” ( “L” is under white light (0.4 W cm
-2) for 10 min; concentrations of Cor-AIE dots are 1 mg mL
-1 based on TPP-TPA; volume of injection is 150 μL) .
The following definitions are provided for the purpose of understanding the present subject matter and for constructing the appended patent claims.
Definitions
It should be understood that the drawings described above or below are for illustration purposes only. The drawings are not necessarily to scale, with emphasis generally being placed upon illustrating the principles of the present teachings. The drawings are not intended to limit the scope of the present teachings in any way.
Throughout the application, where compositions are described as having, including, or comprising specific components, or where processes are described as having, including, or comprising specific process steps, it is contemplated that compositions of the present teachings can also consist essentially of, or consist of, the recited components, and that the processes of the present teachings can also consist essentially of, or consist of, the recited process steps.
In the application, where an element or component is said to be included in and/or selected from a list of recited elements or components, it should be understood that the element or component can be any one of the recited elements or components, or the element or component can be selected from a group consisting of two or more of the recited elements or components. Further, it should be understood that elements and/or features of a composition, an apparatus, or a method described herein can be combined in a variety of ways without departing from the spirit and scope of the present teachings, whether explicit or implicit herein
The use of the terms "include, " "includes" , "including, " "have, " "has, " or "having" should be generally understood as open-ended and non-limiting unless specifically stated otherwise.
The use of the singular herein includes the plural (and vice versa) unless specifically stated otherwise.
It should be understood that the order of steps or order for performing certain actions is immaterial so long as the present teachings remain operable. Moreover, two or more steps or actions may be conducted simultaneously.
The term “λ
ex” as used herein refers to excitation wavelength.
The phrase “aggregation caused quenching” or “ACQ” as used herein refers to the phenomenon wherein the aggregation of π-conjugated fluorophores significantly decreases the fluorescence intensity of the fluorophores. The aggregate formation is said to “quench” light emission of the fluorophores.
The phrase “aggregation induced emission” or “AIE” as used herein refers to the phenomenon manifested by compounds exhibiting significant enhancement of light-emission upon aggregation in the amorphous or crystalline (solid) states whereas they exhibit weak or almost no emission in dilute solutions.
“Emission intensity” as used herein refers to the magnitude of fluorescence/phosphorescence normally obtained from a fluorescence spectrometer or fluorescence microscopy measurement; “fluorophore” or “fluorogen” as used herein refers to a molecule which exhibits fluorescence; “luminogen” or “luminophore” as used herein refers to a molecule which exhibits luminescence; and “AIEgen” as used herein refers to a molecule exhibiting AIE characteristics.
As used herein, “halo” or “halogen” refers to fluoro, chloro, bromo, and iodo.
As used herein, “alkyl” refers to a straight-chain or branched saturated hydrocarbon group. Examples of alkyl groups include methyl (Me) , ethyl (Et) , propyl (e.g., n-propyl and z'-propyl) , butyl (e.g., n-butyl, z'-butyl, sec-butyl, tert-butyl) , pentyl groups (e.g., n-pentyl, z'-pentyl, -pentyl) , hexyl groups, and the like. In various embodiments, an alkyl group can have 1 to 40 carbon atoms (i.e., C1-40 alkyl group) , for example, 1-30 carbon atoms (i.e., C1-30 alkyl group) . In some embodiments, an alkyl group can have 1 to 6 carbon atoms, and can be referred to as a “lower alkyl group” . Examples of lower alkyl groups include methyl, ethyl, propyl (e.g., n-propyl and z'-propyl) , and butyl groups (e.g., n-butyl, z'-butyl, sec-butyl, tert-butyl) . In some embodiments, alkyl groups can be substituted as described herein. An alkyl group is generally not substituted with another alkyl group, an alkenyl group, or an alkynyl group.
As used herein, “alkenyl” refers to a straight-chain or branched alkyl group having one or more carbon-carbon double bonds. Examples of alkenyl groups include ethenyl, propenyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl groups, and the like. The one or more carbon-carbon double bonds can be internal (such as in 2-butene) or terminal (such as in 1-butene) . In various embodiments, an alkenyl group can have 2 to 40 carbon atoms (i.e., C2-40 alkenyl group) , for example, 2 to 20 carbon atoms (i.e., C2-20 alkenyl group) . In some embodiments, alkenyl groups can be substituted as described herein. An alkenyl group is generally not substituted with another alkenyl group, an alkyl group, or an alkynyl group.
As used herein, “heteroatom” refers to an atom of any element other than carbon or hydrogen and includes, for example, nitrogen, oxygen, silicon, sulfur, phosphorus, and selenium.
As used herein, “aryl” refers to an aromatic monocyclic hydrocarbon ring system or a polycyclic ring system in which two or more aromatic hydrocarbon rings are fused (i.e., having a bond in common with) together or at least one aromatic monocyclic hydrocarbon ring is fused to one or more cycloalkyl and/or cycloheteroalkyl rings. An aryl group can have 6 to 24 carbon atoms in its ring system (e.g., C6-24 aryl group) , which can include multiple fused rings. In some embodiments, a polycyclic aryl group can have 8 to 24 carbon atoms. Any suitable ring position of the aryl group can be covalently linked to the defined chemical structure. Examples of aryl groups having only aromatic carbocyclic ring (s) include phenyl, 1-naphthyl (bicyclic) , 2-naphthyl (bicyclic) , anthracenyl (tricyclic) , phenanthrenyl (tricyclic) , pentacenyl (pentacyclic) , and like groups. Examples of polycyclic ring systems in which at least one aromatic carbocyclic ring is fused to one or more cycloalkyl and/or cycloheteroalkyl rings include, among others, benzo derivatives of cyclopentane (i.e., an indanyl group, which is a 5, 6-bicyclic cycloalkyl/aromatic ring system) , cyclohexane (i.e., a tetrahydronaphthyl group, which is a 6, 6-bicyclic cycloalkyl/aromatic ring system) , imidazoline (i.e., a benzimidazolinyl group, which is a 5, 6-bicyclic cycloheteroalkyl/aromatic ring system) , and pyran (i.e., a chromenyl group, which is a 6, 6-bicyclic cycloheteroalkyl/aromatic ring system) . Other examples of aryl groups include benzodioxanyl, benzodioxolyl, chromanyl, indolinyl groups, and the like. In some embodiments, aryl groups can be substituted as described herein. In some embodiments, an aryl group can have one or more halogen substituents, and can be referred to as a “haloaryl” group. Perhaloaryl groups, i.e., aryl groups where all of the hydrogen atoms are replaced with halogen atoms (e.g., -C
6F
5) , are included within the definition of “haloaryl” . In certain embodiments, an aryl group is substituted with another aryl group and can be referred to as a biaryl group. Each of the aryl groups in the biaryl group can be substituted as disclosed herein.
As used herein, “heteroaryl” refers to an aromatic monocyclic ring system containing at least one ring heteroatom selected from oxygen (O) , nitrogen (N) , sulfur (S) , silicon (Si) , and selenium (Se) or a polycyclic ring system where at least one of the rings present in the ring system is aromatic and contains at least one ring heteroatom. Polycyclic heteroaryl groups include those having two or more heteroaryl rings fused together, as well as those having at least one monocyclic heteroaryl ring fused to one or more aromatic carbocyclic rings, non-aromatic carbocyclic rings, and/or non-aromatic cycloheteroalkyl rings. A heteroaryl group, as a whole, can have, for example, 5 to 24 ring atoms and contain 1-5 ring heteroatoms (i.e., 5-20 membered heteroaryl group) . The heteroaryl group can be attached to the defined chemical structure at any heteroatom or carbon atom that results in a stable structure. Generally, heteroaryl rings do not contain O-O, S-S, or S-0 bonds. However, one or more N or S atoms in a heteroaryl group can be oxidized (e.g., pyridine Noxide thiophene S-oxide, thiophene S, S-dioxide) . Examples of heteroaryl groups include, for example, the 5-or 6-membered monocyclic and 5-6 bicyclic ring systems shown below:
where T is O, S, NH, N-alkyl, N-aryl, N- (arylalkyl) (e.g., N-benzyl) , SiH2, SiH (alkyl) , Si (alkyl) 2, SiH (arylalkyl) , Si (arylalkyl) 2, or Si (alkyl) (arylalkyl) . Examples of such heteroaryl rings include pyrrolyl, furyl, thienyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, isothiazolyl, thiazolyl, thiadiazolyl, isoxazolyl, oxazolyl, oxadiazolyl, indolyl, isoindolyl, benzofuryl, benzothienyl, quinolyl, 2-methylquinolyl, isoquinolyl, quinoxalyl, quinazolyl, benzotriazolyl, benzimidazolyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzoxadiazolyl, benzoxazolyl, cinnolinyl, lH-indazolyl, 2H-indazolyl, indolizinyl, isobenzofuyl, naphthyridinyl, phthalazinyl, pteridinyl, purinyl, oxazolopyridinyl, thiazolopyridinyl, imidazopyridinyl, furopyridinyl, thienopyridinyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, thienothiazolyl, thienoxazolyl, thienoimidazolyl groups, and the like. Further examples of heteroaryl groups include 4, 5, 6, 7-tetrahydroindolyl, tetrahydroquinolinyl, benzothienopyridinyl, benzofuropyridinyl groups, and the like. In some embodiments, heteroaryl groups can be substituted as described herein.
As used herein, a "donor" material refers to an organic material, for example, an organic nanoparticle material, having holes as the majority current or charge carriers.
As used herein, an "acceptor" material refers to an organic material, for example, an organic nanoparticle material, having electrons as the majority current or charge carriers.
As used herein, a "theranostic agent" refers to an organic material, for example, an organic nanoparticle material, having both diagnostic and therapeutic capabilities.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which the presently described subject matter pertains.
Where a range of values is provided, for example, concentration ranges, percentage ranges, or ratio ranges, it is understood that each intervening value, to the tenth of the unit of the lower limit, unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the described subject matter. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and such embodiments are also encompassed within the described subject matter, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the described subject matter.
Throughout the application, descriptions of various embodiments use “comprising” language. However, it will be understood by one of skill in the art, that in some specific instances, an embodiment can alternatively be described using the language “consisting essentially of” or “consisting of” .
For purposes of better understanding the present teachings and in no way limiting the scope of the teachings, unless otherwise indicated, all numbers expressing quantities, percentages or proportions, and other numerical values used in the specification and claims, are to be understood as being modified in all instances by the term “about” . Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. In addition, where the use of the term "about" is before a quantitative value, the present teachings also include the specific quantitative value itself, unless specifically stated otherwise. As used herein, the term "about" refers to a ±10%variation from the nominal value unless otherwise indicated or inferred.
Fluorescent Compounds and Compositions
The present subject matter contemplates a fluorescent compound having aggregation-induced emission (AIE) characteristics and exhibiting near infrared absorption. The compound can have a rotor-rich skeleton and an inherent charge. The compound can be in nanoparticle form.
Also provided are compositions including the fluorescent compound and corannulene-modified polyethylene glycol encapsulating the fluorescent compound. The compositions can be in nanoparticle form. The fluorescent compound can be encapsulated by the corannulene-modified polyethylene glycol using nanoprecipitation under ultrasonic conditions. Compositions including the nanoparticle form of the fluorescent compound and the corannulene-modified polyethylene glycol are also referred to herein as “theranostic agents” or “Cor-AIE dots” .
Encapsulating the fluorescent compound in a corannulene encapsulation matrix can enhance the intra-particle microenvironment and thereby provide enhanced fluorescence and ROS generation capacity in vivo. The corannulene matrix can provide intra-particle rigidity and restrict intramolecular rotation of the encapsulated compound, leading to highly suppressed non-radiative decay. The absorbed energy can flow to both the fluorescence pathway and the intersystem crossing (ISC) process. Intersystem crossing (ISC) from S
1 to the lowest excited triplet state (T
1) can result from the small S
1-T
1 energy gap, and result in ROS production via energy transfer (ET) from T
1 to ambient oxygen (O
2) .
Accordingly, the present compounds and compositions can be beneficial in diagnostic and phototheranostic applications, particularly with respect to NIR imaging-guided cancer surgery and photodynamic cancer therapy.
In an embodiment, the compounds have a backbone structural formula selected from the group consisting of:
wherein each R
1, R
1′, R
1”and R
1”’is independently selected from the group consisting of
wherein each R
2, R
3, R
4, R
5, R
6, and R
7 is independently selected from the group consisting of H, alkyl, unsaturated alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C
nH
2n+1, C
10H
7, C
12H
9, alkoxy, OC
6H
5, OC
10H
7 and OC
12H
9, C
nH
2nCOOH, C
nH
2nNCS, C
nH
2nN
3, C
nH
2nNH
2, C
nH
2nSH, C
nH
2nCl, C
nH
2nBr, C
nH
2nI, N (C
nH
m)
2, and SC
nH
m;
wherein n and m are each independently an integer from 0-10;
wherein A is a monovalent counter ion; and
wherein the monovalent counter ion is always present in the compound.
In a further embodiment, the compound is:
In yet another embodiment, the present subject matter relates to a fluorescent nanoparticle composition, comprising a fluorescent compound exhibiting aggregation induced emission properties and corannulene-modified polyethylene glycol, the corannulene-modified polyethylene glycol encapsulating the fluorescent compound, the fluorescent compound having a backbone structural formula selected from the group consisting of:
wherein each R
1, R
1′, R
1”and R
1”’is independently selected from the group consisting of
wherein each R
2, R
3, R
4, R
5, R
6, and R
7 is independently selected from the group consisting of H, alkyl, unsaturated alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C
nH
2n+1, C
10H
7, C
12H
9, alkoxy, OC
6H
5, OC
10H
7 and OC
12H
9, C
nH
2nCOOH, C
nH
2nNCS, C
nH
2nN
3, C
nH
2nNH
2, C
nH
2nSH, C
nH
2nCl, C
nH
2nBr, C
nH
2nI, N (C
nH
m)
2, and SC
nH
m, ;
wherein n and m are each independently an integer from 0-10;
wherein A is a monovalent counter ion selected from the group consisting of I
-, Cl
-, Br
-, PF
6
-, ClO
4
-, BF
4
-, BPh
4
-, and CH
3PhSO
3
-; and
wherein the monovalent counter ion is always present in the compound.
In a further embodiment, the fluorescent compound of the composition can be:
An exemplary reaction scheme for preparing the inherently-charged TPP-TPA compound is as provided below:
To extend the emission spectrum of the compound to NIR range, two electron-donating diphenylamine groups and one electron-withdrawing 1-methylpyridinium unit is incorporated into triphenylethene. Strong electron donor-acceptor interactions endow TPP-TPA with a large dipole moment. The large number of rotatable aryl rings makes the skeleton of TPP-TPA flexible. Compound 1 is obtained with a high yield of 95%according to a known procedure, and subsequently reacted with (4-methoxy-phenyl) -pyridin-4-yl-methanone undergoing McMurry coupling to yield compound 2 in 70%. Reaction of compound 2 with iodomethane followed by ion-exchange reaction with potassium hexafluorophosphate gives the desirable product TPP-TPA in a high yield of 99%. All intermediates and product of this reaction were characterized by NMR and mass spectroscopies, from which satisfactory data corresponding to their structures were obtained (Figs. 2-8) .
Cancer diagnostics and/or cancer therapy
The theranostic agents described herein can be beneficial in cancer diagnostic and phototheranostic applications, particularly with respect to NIR imaging-guided cancer surgery and photodynamic cancer therapy. Image-guided cancer surgery using NIR fluorescence has been verified to be feasible during clinical cancer surgery, and holds great promise for successful outcomes in cancer surgery. The theranostic agents described herein can be used as efficient NIR fluorescent probes that meet the necessary requirements of image-guided cancer surgery.
As described herein, compositions including TPP-TPA and lipid-PEG (DSPE-PEG: 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-N- [methoxy (polyethylene glycol) -2000] ) and compositions including corannulene-modified PEG (Cor-PEG) , respectively, afforded two types of AIE dots with different intra-particle rigid microenvironments. Corannulene is a polyaromatic hydrocarbon from a part of C
60 and is well-known in organic optoelectronics due to its uneven electron distribution, electron-negative core, and electron-positive periphery. Corannulene possesses a bowl shape with large curvature that inhibits bowl-to-bowl inversion at room temperature, owing to the large energy barrier of 11.5 kcal/mol. Hence, corannulene possesses a large dipole moment of 2.1D, superhydrophobicity, and hyper-rigidity. Corannulene typically has a chemical formula of C
20H
10. The molecule consists of a cyclopentane ring fused with 5 benzene rings, so another name for it is [5] circulene. Corannulene has a typical structure of:
As compared to TPP-TPA-loaded DSPE-PEG nanodots (DSPE-AIE dots) with relatively low NIR fluorescence and weak ROS generation capability, the TPP-TPA-loaded Cor-PEG nanodots (Cor-AIE dots) show 4.0-fold amplified fluorescence quantum yield and 5.4-fold enhanced ROS production.
1H NMR titration and theoretical calculations essentially demonstrate that the corannulene provides intra-particle rigidity and strong interactions with TPP-TPA, which restrict intramolecular rotation of the encapsulated AIEgens, leading to highly suppressed nonradiative decay. The absorbed energy thus flows to both the fluorescence pathway and ISC process. As described herein, this highly amplified NIR emission and ROS generation capacity demonstrated significant phototheranostic efficacies in terms of NIR imaging-guided cancer surgery and photodynamic cancer therapy using a peritoneal carcinomatosis-bearing mouse model. Since, to date, DSPE-PEG has been the most widely used encapsulation matrix for building AIE dots, the comparative studies described herein not only provide a new strategy and molecular guideline to prepare superior AIE dots, but also bring new insights into the design of advanced fluorescent NPs for biomedical applications.
According to an embodiment, the present subject matter relates to a method of killing cancer cells, which can include contacting the theranostic agent with a target cancer cell, imaging the target cancer cell while the theranostic agent contacts the target cancer cell, and subjecting the target cancer cell to near infrared light irradiation while the theranostic agent contacts the target cancer cell to kill the target cancer cell. The imaging method can be selected from fluorescence microscopy, bioluminescence imaging, and confocal laser scanning microscopy. The theranostic agent can be combined with a buffer solution prior to contacting the target cancer cell.
According to an embodiment, the present subject matter relates to a method of locating a tumor site in a patient, which can include administering the theranostic agent to the patient, contacting a tumor site with the theranostic agent, and locating the tumor site using an imaging method after the tumor site is contacted with the theranostic agent. The theranostic agent can be administered by intravenous injection. The theranostic agent can be combined with a buffer solution prior to administering the theranostic agent to the patient. The imaging method can include at least one of fluorescence microscopy, bioluminescence imaging, and confocal laser scanning microscopy. Luciferin can be administered to the patient prior to use of bioluminescence imaging. Once the tumor site has been determined, the tumor site can be irradiated with near-infrared light radiation which, when combined with the present compounds, can stop or inhibit the growth of the tumor. In an embodiment, the compounds can be administered to the patient six hours prior to imaging and treatment of the tumor.
According to an embodiment, the present subject matter relates to a method of stopping or inhibiting tumor growth in a patient, which can include administering the theranostic agent to the patient; contacting a tumor site with the theranostic agent; locating the tumor site using an imaging method after the tumor site is contacted with the theranostic agent; and subjecting the tumor site to near-infrared light irradiation while the theranostic agent is present at the tumor site to stop or inhibit the growth of the tumor. Subjecting the tumor site to near-infrared light irradiation while the theranostic agent is present at the tumor site generates reactive oxygen species to stop or inhibit the growth of the tumor. The theranostic agent can be administered by intravenous injection. The theranostic agent can be combined with a buffer solution prior to administering the theranostic agent to the patient. The imaging method can include at least one of fluorescence microscopy, bioluminescence imaging, and confocal laser scanning microscopy. Luciferin can be administered to the patient prior to use of bioluminescence imaging.
The present teachings are illustrated by the following examples.
EXAMPLES
Materials and Instruments
THF (Labscan) was purified by simple distillation from sodium benzophenone ketyl under nitrogen immediately before use. Zinc dust, titanium (IV) chloride, 4, 4'-difluorobnzophenone, diphenylamine, potassium tert-butoxide (t-BuOK) , 4-methoxyphenyl-4-pyridylketon, iodomethane (CH
3I) , potassium hexafluorophosphate (KPF
6) , H2DCF-DA, dimethyl sulfoxide (DMSO) , and other reagents were all purchased from Aldrich and used as received. Milli-Q water was supplied by Milli-Q Plus System (Millipore Corporation, United States) . Minimum essential medium (MEM) , Dulbecco’s modified eagle medium (DMEM) , fetal bovine serum (FBS) , penicillin and streptomycin, and phosphate buffered saline (PBS) were purchased from Invitrogen.
1H and
13C NMR spectra were measured on Bruker ARX 400 NMR spectrometers using CD
2Cl
2 as the deuterated solvent. High-resolution mass spectrometry (HRMS) were recorded on a Finnegan MAT TSQ 7000 Mass Spectrometer System operating in a MALDI-TOF mode. UV absorption spectra were taken on a Milton Ray Spectronic 3000 array spectrophotometer. Steady-state fluorescence spectra were recorded on a Perkin Elmer LS 55 spectrometer. Fluorescence images were collected on Olympus BX 41 fluorescence microscope. Laser confocal scanning microscope images were collected on Zeiss laser scanning confocal microscope (LSM7 DUO) and analyzed using ZEN 2009 software (Carl Zeiss) . The observation of nanoparticle morphology was investigated using transmission electron microscopy (TEM, JEM-2010F, JEOL, Japan) . Size distribution of nanoparticles was conducted on dynamic light scattering (DLS) with a particle size analyzer (90 Plus, Brookhaven Instruments Co. USA) at a fixed angle of 90° at room temperature.
For cell culturing, luciferase-expressed 4T1 breast cancer cells and human HeLa cancer cells were cultured in the DMEM containing 10%FBS and antibiotics (100 units/mL penicillin and 100 g/mL streptomycin) in a 5%CO
2 humidity incubator at 37 ℃. MDCK-II, U87 cells were cultured in the DMEM containing 10%FBS and antibiotics (100 units/mL penicillin and 100 g/mL streptomycin) in a 5%CO
2 humidity incubator at 37 ℃.
For cell imaging, cells were grown overnight on a 35 mm petri dish with a cover slip or a plasma-treated 25 mm round cover slip mounted at the bottom of a 35 mm petri dish with an observation window. The live cells were incubated with Cor-AIE dots at certain concentration for certain time. The dye-labelled cells were mounted and imaged under Zeiss laser scanning confocal microscope (LSM7 DUO) . Conditions were as follows: for Cor-AIE dots, excitation laser: 560 nm, emission collection: 570-720 nm; for Hoechst 33342, excitation laser: 405 nm, emission collection: 430-470 nm.
For the histological study, the excised tumors of the mice were fixed in 4%formalin, processed into paraffin, sectioned at 5 μm thickness, and stained with hematoxylin and eosin (H&E) . The slices were examined by a digital microscope (Leica QWin) .
Quantitative data were expressed as mean ± standard deviation. Statistical comparisons were made by ANOVA analysis and Student’s t-test. P value < 0.05 was considered statistically significant.
Example 1
Synthesis of Compound 2
Compound 2: TiCl
4 (1 mL, 9.0 mmol) was slowly added into a suspension of Zn dust (1.17 g, 18.0 mmol) in dry THF (50 mL) under -78 ℃. After reflux for 2 h, a mixture of compound 1 (2.325 g, 4.5 mmol) and 4-methoxyphenyl-4-pyridylketon (0.640 g, 3 mmol) in dry THF (20 mL) was added to the reaction. The mixture was allowed to continue reflux for another 5 h. After removal of the solvent by compressed air, the residue was extracted by DCM and dried over anhydrous Na
2SO
4. The crude product was purified on a silica-gel column using DCM as eluent. Compound 2 was isolated as a yellow solid in 70%yield.
1H NMR (400 MHz, CD
2Cl
2, δ) : 8.33 (d, 2H, J= 0.011) , 7.27-7.22 (m, 8H) , 7.05-7.03 (m, 9H) , 7.02-7.01 (m, 2H) , 7.00-6.99 (m, 1H) , 6.97 (d, 2H, J= 0.013) , 6.95 (d, 2H, J=0.011) , 6.93 (d, 2H, J=0.004) , 6.92 (d, 2H, J =0.007) , 6.82 (d, 2H, 0.004) , 6.79 (d, 2H, 0.005) , 6.71 (d, 2H, J= 0.021) , 3.77 (s, 3H) ;
13C NMR (100 MHz, CD
2Cl
2, δ) : 158.50, 152.44, 148.92, 147.55, 147.50, 146.80, 146.49, 142.31, 137.21, 136.89, 136.76, 135.15, 132.52, 132.14, 132.07, 129.22, 129.17, 126.13, 124.45, 124.35, 122.99, 122.91, 122.51, 113.19, 55.12; HRMS (m/z) calcd. for C
50H
39NO
3 [M]
+: 697.3093; found, 697.3121.
Example 2
Synthesis of TPP-TPA
Compound 2 (0.174g, 0.25 mmol) was dissolved in 20 mL toluene, after which 0.1 mL of CH
3I (large overdose) was added to form a mixture. The reaction mixture was refluxed overnight. After cooling to room temperature, the precipitates were filtered and washed with cold toluene three times. The obtained solid was dissolved in 20 mL acetone and 100 mg of KPF
6 was added for ion-exchange for 2 h. The solvent was removed and the solid was washed with water. Pure yellow product of TPP-TPA was obtained by recrystallization from DCM/hexane mixture (1: 5 by volume) in 99%yield.
1H NMR (400 MHz, CD
2Cl
2, δ) : 8.11 (d, 2H, J = 0.016) , 7.45 (d, 2H, J = 0.016) , 7.33-7.30 (m, 4H) , 7.28-7.24 (m, 4H) , 7.13-7.08 (m, 7H) , 7.07-7.04 (m, 5H) , 6.98-6.93 (m, 4H) , 6.90-6.85 (m, 4H) , 6.80-6.75 (m, 4H) , 4.20 (s, 3H) , 3.79 (s, 3H) ;
13C NMR (100 MHz, CD
2Cl
2, δ) : 162.95, 159.34, 151.19, 148.96, 148.05, 147.03, 146.84, 142.76, 134.81, 133.82, 133.40, 132.92, 132.75, 132.60, 129.64, 129.51, 129.33, 125.53, 125.10, 124.10, 123.69, 121.12, 120.89, 114.17, 55.26, 47.43; HRMS (m/z) calcd. for C
29H
28NO
3
+ [M-PF
6]
+: 712.3322; found, 712.3315.
Example 3
Preparation and Characterization of Cor-AIE dots and DSPE-AIE dots
Cor-PEG or DSPE-PEG (1 mg) powder and TPP-TPA (0.2 mg) were completely dissolved in THF (1 mL) . After that, the THF solution was added into 9 mL Milli-Q water (18.2 MU) slowly under continuous ultrasound (125 W) . The mixed solution was further kept in ultrasound for another 1 minute, then the THF was removed by evaporation while stirring under N
2 at room temperature. Finally, the clear solution was obtained for use.
Example 4
Photophysical properties
UV-vis absorption and photoluminescence (PL) spectra of TPP-TPA are reflected in Figs. 8 and 1A. TPP-TPA absorbs at 440 nm with the absorption tail extended to 600 nm in DMSO, covering most of visible light range. Such solution emits almost no light even when increasing the water fraction (f
w) in the DMSO-H
2O mixture up to 50%, which can be ascribed to the active intramolecular rotation of the aryl rings (Fig. 1C) . The emission of TPP-TPA was enhanced dramatically when the f
wwas over 50%. Fig. 1B shows the plot of emission intensity at 680 nm against f
w and the inset fluorescent photos of the red emission in the 99%aggregated solution compared to the negligible emission in DMSO. As shown in Fig. 1B, TPP-TPA exhibited typical AIE characteristics. Notably, the emission intensity slightly decreased after the f
w exceeded 80%, which is mainly attributed to the serious twisted intramolecular charge transfer (TICT) effect in the polar solvent water. Such effect can be further supported by the emission red shift of 10 nm from 80%to 99% (Fig. 9) and can also be indicated by the typical electron distribution of HOMO and LUMO in both ground and excited states (Figs. 1C and Figs. 10A-10B) . Additionally, the Stokes shift for TPP-TPA was evaluated to be 220 nm, which is much larger than the small Stokes shifts of less than 50 nm of most commercial NIR fluorophores, avoiding the light contamination of excitation light and self-absorption of emission during biomedical imaging.
Example 5
Preparation, photophysical properties, and ROS production of DSPE-AIE dots
and Cor-AIE dots
The TPP-TPA-loaded NPs, were prepared by a nanoprecipitation method as shown in Fig. 11. TPP-TPA was formulated using corannulene-modified polyethylene glycol ( “Cor-PEG” ) having a bowl-shaped corannulene and 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol) -2000] ( “DSPE-PEG” ) with linear alkyl chain as the encapsulation matrix, respectively, obtaining Cor-AIE dots and DSPE-AIE dots, which possess similar absorption to TPP-TPA itself in aqueous media (Fig. 12) . The sizes of Cor-AIE dots and DSPE-AIE dots were recorded by dynamic light scattering (DLS) with the values of 46.9 nm and 49.1 nm, respectively (Figs. 13A and 13B) . TEM was further used to confirm these nanoparticles bearing the spherical shape (Figs. 13C and 13D) . As suggested in Figs. 14A and 14B, Cor-AIE dots exhibited stronger emission with the quantum yield of 26.8%, which is four times larger than 6.7%for DSPE-AIE dots. In addition, the average fluorescence lifetime of Cor-AIE dots was measured to be 4.34 ns, which is about four times that of DSPE-AIE dots. The possibility of fluorescence resonance energy transfer (FRET) from corannulene to TPP-TPA can be completely ruled out because the whole absorption spectrum of corannulene is located on the UV range and its emission cannot reach the excitation of 500 nm. Therefore, it is likely that such enhanced emission and lengthened fluorescence lifetime originates from the enhanced radiative pathway of TPP-TPA.
Furthermore, 9, 10-anthracenediyl-bis (methylene) dimalonic acid (ABDA) , a commercially available ROS indicator, was used to evaluate the ROS production capacities of Cor-AIE dots and DSPE-AIE dots. Noteworthy, the absorbance of ABDA in water dramatically decreased in the presence of Cor-AIE dots (Up in Fig. 14C) under white light irradiation, whereas faint decrease of ABDA absorbance was observed for DSPE-AIE dots (Down in Fig. 14C) , suggesting that Cor-AIE dots were capable of producing more ROS to decompose ABDA more quickly than DSPE-AIE dots under the same experimental conditions. Plotting of the decomposition rate of ABDA in Fig. 14D quantitatively reveals that the ROS generation ability of Cor-AIE dots is around 5.4 times better than that of DSPE-AIE dots, indicative of the far higher ROS production efficiency of Cor-AIE dots.
Example 6
1H titration and theoretical calculation
The underlying principle of the significantly enhanced fluorescence and ROS production described in Example 6 was studied.
1H NMR titration experiment was first conducted to investigate the interactions between corannulene and TPP-TPA (Fig. 15A) . Upon stepwise addition of corannulene into the CD
2Cl
2 solution of TPP-TPA, the signals of the aromatic protons in 1-methylpyridinium of TPP-TPA gradually shifted upfield by 0.08 ppm (H
ain Fig. 15B) and 0.05 ppm (H
b in Fig. 15D) , while those of the protons in corannulene shifted by about 0.03 ppm (H
e) (Fig. 15C) to the higher field. Meanwhile, the methyl protons in 1-methylpyridinium (H
c) and methoxyphenyl (H
d) moieties of TPP-TPA were also shifted by around 0.07 ppm and 0.02 ppm upfield, respectively (Fig. 15E) . These chemical shifts evidently imply the unique interactions and the probably-relative positions between corannulene and TPP-TPA, with the positively-charged 1-methylpyridinium of TPP-TPA close to the electronegative bottom of corannulene and the TPA and methoxyphenyl units of TPP-TPA outside the bowl of corannulene. Some possible theoretical positions of corannulene and TPP-TPA are shown in Fig. 16A, which can result in the shielding effect of corannulene for 1-methylpyridinium of TPP-TPA. Density functional theory (DFT) calculation based on TD-DFT/M06-2X/6-31G (d) method was also used to study the ISC process (Fig. 16B) . The related optimized molecular geometries of S
0, S
1 and T
1 states for TPP-TPA at M06-2X/6-31G (d) level were calculated in the absence and presence of corannulene. The gaps between the S
1 and T
1 states (ΔE
ST) for TPP-TPA upon the interaction with corannulene were significantly decreased compared with that for TPP-TPA alone, and the respective SOC constants (ξ (S
1, T
1) ) between S
1 and T
1 were also increased, suggesting the more accessible ISC process in the presence of corannulene.
The bowl-shaped corannulene possesses a super-hydrophobic skeleton and an ultra-rigid curvature compared with the flexible alkyl-chained DSPE, and hence constructs a more confined microenvironment in aqueous solution. Corannulene bears a large dipole moment and the bottom of the corannulene bowl is electronegative with the periphery being electropositive, which attracts inherent positively-charged TPP-TPA by dipole-dipole and electrostatic interactions. Compared to the intra-particle microenvironment of DSPE-AIE dots, the more confined and rigid micro-cavity within Cor-AIE dots (resulting from the uniqueness of corannulene structure as well as the strong interactions between corannulene and TPP-TPA) restricts the intramolecular rotation of the phenyl rings in TPP-TPA to a much greater extent than that of DSPE-AIE dots, and thus inhibits nonradiative relaxation more effectively (Figs. 14E-14F) . As the absorbed energy of TPP-TPA is fixed, the highly suppressed nonradiative decay for Cor-AIE dots reasonably makes its absorbed energy flow to both the fluorescence pathway and ISC process, achieving significantly amplified emission and ROS generation. This is supported by the theoretical formulas of Φ
F = k
r/ (k
r+k
nr+k
ISC) and Φ
ISC = k
ISC/ (k
r+k
nr+k
ISC) , where the dramatic decrease in nonradiative rate k
nr undoubtedly induces the extensive increase of the fluorescence emission efficiency Φ
F and the ISC efficiency Φ
ISC. In addition, as TPP-TPA has strong electron donor-acceptor structures in the backbone, the fast process of charge transfer-induced fluorescence quenching in aqueous media competes with ROS production. Cor-AIE dots can also provide a more isolated hydrophobic environment to reduce the polar-solvent disruption (such as TICT) for TPP-TPA, bringing about further enhancement of emission efficiency and ROS production. Indeed, the reduced TICT effect in Cor-AIE dots was reflected by the slight blue shift of about 10 nm in the emission spectrum compared to DSPE-AIE dots (Fig. 14A) .
Example 7
Cancer phototheranostics
Due to the excellent NIR emission output and ROS production, the utility and strength of Cor-AIE dots in cancer phototheranostics were investigated. After it was demonstrated that Cor-AIE dots could be internalized in cancer cells and generate ROS within cells effectively (Figs. 17A-17I) , in vivo studies were carried out using a peritoneal carcinomatosis-bearing mouse model, which was established by intraperitoneal inoculation of murine 4T1 cancer cells, as described below. All animal studies were performed in compliance with the guidelines set by Tianjin Committee of Use and Care of Laboratory Animals and the overall project protocols were approved by the Animal Ethics Committee of Nankai University. All the mice were obtained from Laboratory Animal Center of the Academy of Military Medical Sciences (Beijing, China) .
To establish peritoneal carcinomatosis-bearing mouse model, a total of 300,000 luciferase-expressed 4T1 cancer cells in 0.1 mL of PBS buffer were intraperitoneally injected into the Balb/c mice. After about 5 days, small tumor nodules were formed and scattered in the mouse peritoneal cavity, which could be detected by bioluminescence imaging upon injection of a solution of D-luciferin (150 mg/kg) . It is worthy to note that the in vivo inoculated 4T1 cancer cells express luciferase. As such, the living cancer cells emitted bioluminescence when the tumor-bearing mice were administered with the substrate of luciferase (D-luciferin) , allowing for precise tracking of the tumor nodules in the mouse peritoneal cavity.
NIR fluorescence image-guided surgery
An experiment was conducted to determine whether the highly boosted NIR fluorescence in Cor-AIE dots can be used in image-guided cancer surgery. In this experiment, the peritoneal carcinomatosis-bearing mouse model was selected because of the large number of tumor nodules, especially those with diameters < 1 mm, present in the mouse peritoneal cavity. In practice, the submillimeter tumor nodules are generally difficult for a surgeon to spot and are often missed. These missed small tumors are the major culprits for in situ cancer recurrence. Prior NIR fluorescent probes have generally been incapable of accurately locating the submillimeter tumors, mainly because of the low NIR emission output of these probes.
150 μL of Cor-AIE dots (1 mg mL
-1 based on TPP-TPA) was intravenously injected into the peritoneal carcinomatosis-bearing mice. At 24 h post-injection, the mice were anesthetized. The abdominal cavity of the mice was opened, followed by bioluminescence and fluorescence imaging during surgery. Bioluminescence imaging was performed using the Xenogen
Lumina II system post intraperitoneal injection of D-luciferin (150 mg/kg) into the mice. The bioluminescence signals were quantified in units of maximum photons per second per square centimeter per steridian. Fluorescence imaging was carried out using a Maestro EX in vivo fluorescence imaging system (CRi, Inc.; excitation: 455 nm, spectral imaging from 500 nm to 900 nm) .
In vivo NIR fluorescence imaging during surgery indicated that bright Cor-AIE dot fluorescence clearly lighted up many tissues as well as their boundaries with rather high signal-to-background ratio (Fig. 18A) . As luciferase-expressed 4T1 tumors have bioluminescence, the scattering intraperitoneal tumor nodules were totally and specifically displayed upon bioluminescence imaging post injection with D-luciferin. As shown in Fig. 18A, the bioluminescence signal from luciferase and NIR fluorescence signal from Cor-AIE dots were colocalized perfectly on the surface of the intestines, suggesting that the Cor-AIE dots-visualized tissues are indeed tumors, which are further confirmed by the hematoxylin and eosin (H&E) histological staining. Noteworthy, from in vivo fluorescence imaging, the fluorescence intensity ratio of tumor to normal intestine is as high as 5.2 for Cor-AIE dots, which exceeds the Rose criterion. As depicted in Fig. 18B, the tumor nodules on the peritoneum are also roughed out with an even larger tumor-to-peritoneum ratio of about 8.0. These results quantitatively demonstrate that the Cor-AIE dots possess remarkable EPR effect, permitting high tumor uptake via passive targeting and thus leading to visualization of intraperitoneal tumor nodules and their boundaries in a specific and high-contrast manner. The fluorescence intensity ratios of tumor to normal tissues achieved by Cor-AIE dots are significantly higher than those of many reported NIR fluorescent probes including methylene blue and indocyanine green. More importantly, it is also found that the Cor-AIE dots can distinctly delineate the tumor nodules with sizes < 1 mm in the peritoneal cavity (indicated by the red arrows in Fig. 18) , revealing that Cor-AIE dots are efficacious in sharply visualizing submillimeter tumors due to their highly boosted NIR emission.
As Cor-AIE dots can serve as an extremely effective NIR fluorescent probe to precisely visualize tumors and their boundaries against normal tissues, its application in guidance for surgical tumor removal was studied. To this end, a surgeon from Tianjin First Central Hospital (Tianjin, China) was invited to conduct the operation. 150 μL of Cor-AIE dots (1 mg mL
-1 based on TPP-TPA) was injected into the peritoneal carcinomatosis-bearing mice via the tail vein. After 24 h, tumor resection surgery was first performed by a surgeon from Tianjin First Central Hospital (Tianjin, China) without imaging guidance (unguided) . This was followed by a second surgery on the same mice by the guidance of Cor-AIE dots fluorescence. The excised tumor nodules were analyzed by both fluorescence imaging and bioluminescence imaging. The tumor sizes resected from the first and second surgery were also quantified.
As shown in Figs. 19A and 19B, when the surgeon was blinded to the NIR fluorescence imaging by Cor-AIE dots, he removed many intraperitoneal tumors with relatively large diameters (> 1 mm) . However, after the unguided surgery, there were a number of residual tumor nodules remaining in the peritoneal cavity indicated by Cor-AIE dots, which are mainly the ones with diameters < 1 mm (Fig. 19B) . The surgeon then performed a second operation under the guidance of Cor-AIE dots fluorescence, which achieved almost complete removal of the remaining small tumors (Figs. 19C-E) , confirmed by the negligible intraperitoneal bioluminescence signal. It is noted that all of the harvested tumor nodules (mainly submillimeter ones) in the second operation have bioluminescence signals (Fig. 19D) , validating the precise cancer surgery assisted by Cor-AIE dots. After unguided and Cor-AIE dot fluorescence image-guided surgery, respectively, the survival of the mice was monitored over time with each group containing 10 mice. Due to the high malignancy and fast growth of intraperitoneal 4T1 tumors, all of the 10 mice in the unguided surgery group died within 2 weeks. Encouragingly, 7 of 10 mice in the cohort with Cor-AIE dot fluorescence image-guided surgery were able to survive during a 2 week-monitoring duration (Fig. 20) . These results illustrate that Cor-AIE dots greatly enhance cancer surgery outcome and considerably prolong the lifetimes of tumor-bearing mice post operation by accurately lighting up submillimeter tumor nodules.
Cor-AIE dots in photodynamic tumor therapy
In many cases, surgeons in practice cannot perform tumor-removal operations after opening their patients’abdomen because there are so many small tumors that are difficult to excise manually. As a result, surgeons are forced to close the abdominal wall and choose a treatment strategy other than surgery.
Since in addition to high NIR emission, strong ROS generation ability is the other signature of Cor-AIE dots by virtue of the important contribution of corannulene, the feasibility of Cor-AIE dots in photodynamic tumor therapy was examined in the aforementioned cases in which surgical resection was not feasible after the abdomen was opened. To this end, peritoneal carcinomatosis-bearing mice were randomly divided into 5 groups (n = 8 per group) . which were designated as "Saline" , "Light (L) " , "DSPE-AIE dots + L" , "Cor-AIE dots + L" , and "Cor-AIE dots" . On day 0, bioluminescence imaging was first carried out for all of the mice in the 5 groups. Subsequently, Cor-AIE dots (1 mg mL
-1 based on TPP-TPA; 150 μL) were intravenously injected into the mice in "Cor-AIE dots" and "Cor-AIE dots + L" groups. At 24 h post-injection (day 1) , the mouse abdomen was opened for each mouse in these 2 groups. Then, for each mouse in "Cor-AIE dots + L" group, the whole peritoneal cavity was irradiated with white light (0.4 W cm
-2) for 10 min, followed by closure of the abdomen, utilizing surgical sutures. On the other hand, for mice in "Cor-AIE dots" group, the mouse abdomen was subsequently closed without white light irradiation. For "DSPE-AIE dots + L" group, DSPE-AIE dots (1 mg mL
-1 based on TPP-TPA; 150 μL) were administered to the mice via the tail vein on day 0, followed by the same treatment as that for the mice in "Cor-AIE dots + L" group on day 1. For "Saline" group, saline was intravenously injected into the mice on day 0, followed by the same treatment as that for the mice in "Cor-AIE dots" group on day 1. Finally, for "Light" group, the mice were untreated on day 0, but on day 1, the mice were treated following the same procedure as that for "Cor-AIE dots + L" group. The tumor size and growth were monitored during a 9-day study duration through bioluminescence imaging with the Xenogen
Lumina II system post intraperitoneal injection of D-luciferin (150mg/kg) into the mice. The survival rates were also examined throughout the study.
Fig. 21A and Fig. 22 exhibit time-dependent bioluminescence imaging of the tumor-bearing mice in each group. It was apparent that tumors with intense bioluminescence signal exist in the abdomen of mice before different treatments on day 0. Dramatically, after receiving the treatment of “Cor-AIE dots + L” , the intraperitoneal tumor growth of mice was considerably suppressed, as evidenced by the similar average bioluminescence intensity of intraperitoneal tumors on day 9 to that on day 0 (Fig. 21B) . As controls, both the treatments of “Cor-AIE dots” and “Light (L) ” failed to slow down the growth of intraperitoneal tumors, compared with that of “Saline” (Fig. 22 and Fig. 21B) , revealing that the highly efficacious anticancer activity in “Cor-AIE dots + L” group roots in the PDT via Cor-AIE dots generating ROS in tumors. It is important to note that the PDT of DSPE-AIE dots did not have any inhibitory effects on tumor growth (Fig. 21A and 21B) . This result not only indicates the high malignancy of intraperitoneal tumors, but also implies that the ROS production ability of DSPE-AIE dots is not strong enough to work in this tumor-bearing animal model. The treatment of “Cor-AIE dots + L” lead to greatly prolonged lifetimes of mice and the median survival time for “Cor-AIE dots + L” group was far longer than that for “DSPE-AIE dots + L” group (Fig. 21C) . The sharp comparison in the antitumor efficacy between the PDT of Cor-AIE dots and DSPE-AIE dots reasonably highlights the necessity and importance of the Cor-AIE dots.
The present subject matter being thus described, it will be apparent that the same may be modified or varied in many ways. Such modifications and variations are not to be regarded as a departure from the spirit and scope of the present subject matter, and all such modifications and variations are intended to be included within the scope of the following claims.
Claims (20)
- A fluorescent compound exhibiting aggregation-induced emission properties and near-infrared absorption, the compound having a backbone structural formula selected from the group consisting of:wherein each R 1, R 1′, R 1” and R 1”’ is independently selected from the group consisting ofwherein each R 2, R 3, R 4, R 5, R 6, and R 7 is independently selected from the group consisting of H, alkyl, unsaturated alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C nH 2n+1, C 10H 7, C 12H 9, alkoxy, OC 6H 5, OC 10H 7 and OC 12H 9, C nH 2nCOOH, C nH 2nNCS, C nH 2nN 3, C nH 2nNH 2, C nH 2nSH, C nH 2nCl, C nH 2nBr, C nH 2nI, N (C nH m) 2, and SC nH m;wherein n and m are each independently an integer from 0-10;wherein A is a monovalent counter ion; andwherein the monovalent counter ion is always present in the compound.
- The compound according to claim 1, wherein the compound is in nanoparticle form.
- The compound according to claim 1, wherein the monovalent counter ion is selected from the group consisting of I -, Cl -, Br -, PF 6 -, ClO 4 -, BF 4 -, BPh 4 -, and CH 3PhSO 3 -.
- A theranostic agent comprising the fluorescent compound of claim 1 in nanoparticle form and corannulene-modified polyethylene glycol in nanoparticle form, the corannulene-modified polyethylene glycol encapsulating the fluorescent compound.
- A method of preparing the theranostic agent of claim 5, comprising combining the fluorescent compound with the corannulene-modified polyethylene glycol using nanoprecipitation under ultrasonic conditions.
- A method of killing cancer cells, comprising:contacting a target cancer cell with the theranostic agent according to claim 5;imaging the target cancer cell while the theranostic agent contacts the target cancer cell using an imaging method selected from the group consisting of fluorescence microscopy, bioluminescence imaging, and confocal laser scanning microscopy; andsubjecting the target cancer cell to near infrared light irradiation while the theranostic agent is contacting the target cancer cell to kill the target cancer cell.
- The method of claim 7, further comprising combining the theranostic agent with a buffer solution prior to contacting the target cancer cell.
- A method of locating a tumor site in a patient, comprising:administering the theranostic agent of claim 5 to the patient;contacting the tumor site with the theranostic agent; andlocating the tumor site using an imaging method after the tumor site is contacted with the theranostic agent.
- The method of claim 9, wherein the theranostic agent is administered by intravenous injection.
- The method of claim 9, further comprising combining the theranostic agent with a buffer solution prior to administering the theranostic agent to the patient.
- The method of claim 9, wherein the imaging method comprises at least one of fluorescence microscopy, bioluminescence imaging, and confocal laser scanning microscopy.
- The method of claim 9, further comprising administering luciferin to the patient, wherein the imaging method comprises bioluminescence imaging.
- A method of stopping or inhibiting tumor growth in a patient, comprising:administering the theranostic agent of claim 5 to the patient;contacting a tumor site with the theranostic agent;locating the tumor site using an imaging method after the tumor site is contacted with the theranostic agent; andsubjecting the tumor site to near-infrared light irradiation while the theranostic agent is present at the tumor site to stop or inhibit the growth of the tumor.
- The method of stopping or inhibiting tumor growth in a patient according to claim 14, wherein subjecting the tumor site to near-infrared light irradiation while the theranostic agent is present at the tumor site generates reactive oxygen species to stop or inhibit the growth of the tumor.
- The method of claim 14, wherein the theranostic agent is administered by intravenous injection.
- The method of claim 14, further comprising combining the theranostic agent with a buffer solution prior to administering the theranostic agent to the patient.
- The method of claim 14, wherein the imaging method comprises at least one of fluorescence microscopy, bioluminescence imaging, and confocal laser scanning microscopy.
- A fluorescent nanoparticle composition, comprising a fluorescent compound exhibiting aggregation induced emission properties and corannulene-modified polyethylene glycol, the corannulene-modified polyethylene glycol encapsulating the fluorescent compound, the fluorescent compound having a backbone structural formula selected from the group consisting of:wherein each R 1, R 1′, R 1” and R 1”’ is independently selected from the group consisting ofwherein each R 2, R 3, R 4, R 5, R 6, and R 7 is independently selected from the group consisting of H, alkyl, unsaturated alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C nH 2n+1, C 10H 7, C 12H 9, alkoxy, OC 6H 5, OC 10H 7 and OC 12H 9, C nH 2nCOOH, C nH 2nNCS, C nH 2nN 3, C nH 2nNH 2, C nH 2nSH, C nH 2nCl, C nH 2nBr, C nH 2nI, N (C nH m) 2, and SC nH m, ;wherein n and m are each independently an integer from 0-10;wherein A is a monovalent counter ion selected from the group consisting of I -, Cl -, Br -, PF 6 -, ClO 4 -, BF 4 -, BPh 4 -, and CH 3PhSO 3 -; andwherein the monovalent counter ion is always present in the compound.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201880089767.2A CN111742034B (en) | 2018-02-21 | 2018-06-14 | Bowl-coated AIE nanodots with high non-radiative decay inhibition for enhancing in vivo cancer photodiagnosis and treatment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862710470P | 2018-02-21 | 2018-02-21 | |
US62/710,470 | 2018-02-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019161626A1 true WO2019161626A1 (en) | 2019-08-29 |
Family
ID=67687968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/091220 WO2019161626A1 (en) | 2018-02-21 | 2018-06-14 | Corannulene-incorporated aie nanodots with highly suppressed nonradiative decay for boosted cancer phototheranostics in vivo |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111742034B (en) |
WO (1) | WO2019161626A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113552099A (en) * | 2020-04-24 | 2021-10-26 | 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 | Fluorescent diagnosis kit and application thereof |
CN114349756A (en) * | 2021-12-15 | 2022-04-15 | 南京邮电大学 | AIE organic small molecule and preparation method and application thereof |
CN116400068A (en) * | 2023-02-13 | 2023-07-07 | 泉州圣源警用侦察设备有限公司 | Reagent for revealing potential biological trace containing DNA and revealing method |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116143749A (en) * | 2021-11-23 | 2023-05-23 | 深圳先进技术研究院 | Alanine aggregation-induced emission fluorescent probe and synthesis method and application thereof |
CN114890904B (en) * | 2022-05-30 | 2024-04-19 | 北京大学深圳研究生院 | Compound and interface material for preparing bowl alkenyl perovskite solar cell |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103194215A (en) * | 2013-04-15 | 2013-07-10 | 武汉大学 | Aggregation-induced emission molecule as well as preparation method and use thereof |
WO2016070854A1 (en) * | 2014-11-05 | 2016-05-12 | Benzhong Tang | Photoactivatable bioprobes: design, method of preparation and applications |
-
2018
- 2018-06-14 WO PCT/CN2018/091220 patent/WO2019161626A1/en active Application Filing
- 2018-06-14 CN CN201880089767.2A patent/CN111742034B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103194215A (en) * | 2013-04-15 | 2013-07-10 | 武汉大学 | Aggregation-induced emission molecule as well as preparation method and use thereof |
WO2016070854A1 (en) * | 2014-11-05 | 2016-05-12 | Benzhong Tang | Photoactivatable bioprobes: design, method of preparation and applications |
Non-Patent Citations (2)
Title |
---|
MOUSTAFA T. GABR ET AL.: "Synthesis and aggregation-induced emission properties of pyridine and pyridinium analogues of tetraphenylethylene", RSC ADVANCES, vol. 5, no. 110, 31 December 2015 (2015-12-31), pages 90226 - 90234, XP055633212 * |
XINGGUI GU ET AL.: "Mitochondrion-Specifi c Live- Cell Bioprobe Operated in a Fluorescence Turn-On Manner and a Well-Designed Photoactivatable Mechanism", ADVANCED MATERIALS, vol. 27, no. 44, 7 October 2015 (2015-10-07), pages 7093 - 7100, XP055278311, doi:10.1002/adma.201503751 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113552099A (en) * | 2020-04-24 | 2021-10-26 | 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 | Fluorescent diagnosis kit and application thereof |
CN113552099B (en) * | 2020-04-24 | 2024-04-16 | 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 | Fluorescent diagnostic kit and application thereof |
CN114349756A (en) * | 2021-12-15 | 2022-04-15 | 南京邮电大学 | AIE organic small molecule and preparation method and application thereof |
CN114349756B (en) * | 2021-12-15 | 2024-02-20 | 南京邮电大学 | AIE small organic molecule and preparation method and application thereof |
CN116400068A (en) * | 2023-02-13 | 2023-07-07 | 泉州圣源警用侦察设备有限公司 | Reagent for revealing potential biological trace containing DNA and revealing method |
CN116400068B (en) * | 2023-02-13 | 2023-09-22 | 泉州圣源警用侦察设备有限公司 | Reagent for revealing potential biological trace containing DNA and revealing method |
Also Published As
Publication number | Publication date |
---|---|
CN111742034B (en) | 2023-07-18 |
CN111742034A (en) | 2020-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019161626A1 (en) | Corannulene-incorporated aie nanodots with highly suppressed nonradiative decay for boosted cancer phototheranostics in vivo | |
Zou et al. | Penetration depth tunable BODIPY derivatives for pH triggered enhanced photothermal/photodynamic synergistic therapy | |
Liang et al. | Recent progress in the development of upconversion nanomaterials in bioimaging and disease treatment | |
Zhu et al. | Zwitterionic AIEgens: Rational Molecular Design for NIR‐II Fluorescence Imaging‐Guided Synergistic Phototherapy | |
Wang et al. | Synthesis strategies, luminescence mechanisms, and biomedical applications of near-infrared fluorescent carbon dots | |
Zhen et al. | Efficient red/near‐infrared fluorophores based on benzo [1, 2‐b: 4, 5‐b′] dithiophene 1, 1, 5, 5‐tetraoxide for targeted photodynamic therapy and in vivo two‐photon fluorescence bioimaging | |
CN112566911B (en) | Photothermal reagent | |
Xu et al. | Radical induced quartet photosensitizers with high 1 O 2 production for in vivo cancer photodynamic therapy | |
Nguyen et al. | Design and synthesis of efficient heavy-atom-free photosensitizers for photodynamic therapy of cancer | |
CN114213419B (en) | Fluorescent probe with fluorescence imaging and I-type photodynamic/photothermal cancer cell killing activities as well as preparation method and application thereof | |
Huang et al. | Diketopyrrolopyrrole-Au (I) as singlet oxygen generator for enhanced tumor photodynamic and photothermal therapy | |
CN113831331B (en) | Near infrared two-region aggregation-induced emission molecule for multi-mode imaging and diagnosis and treatment and application thereof | |
Li et al. | Advancing biomedical applications via manipulating intersystem crossing | |
WO2020182174A1 (en) | Aie compounds with fluorescence, photoacoustic, and raman properties | |
Zhang et al. | Highly efficient near-infrared BODIPY phototherapeutic nanoparticles for cancer treatment | |
Xia et al. | Near-infrared organic fluorescent nanoparticles for long-term monitoring and photodynamic therapy of cancer | |
Cong et al. | In vivo photodynamic therapy based on Near-Infrared AIE cationic polymers | |
Hu et al. | A thermally activated delayed fluorescence photosensitizer for photodynamic therapy of oral squamous cell carcinoma under low laser intensity | |
Tian et al. | A feasible molecular engineering for bright π-conjugation free radical photosensitizers with aggregation-induced emission | |
CN114539232B (en) | PH reversible activated near infrared two-region aggregation-induced emission type I photosensitizer and application thereof | |
Li et al. | Rational design of near-infrared platinum (ii)-acetylide conjugated polymers for photoacoustic imaging-guided synergistic phototherapy under 808 nm irradiation | |
CN113683602B (en) | Heptamethine cyanine micromolecule for multi-modal treatment of hypoxic tumors, and preparation method and application thereof | |
CN110950899A (en) | Photo-thermal reagent with ultra-efficient energy barrier-free rotor for photo-thermal therapy and preparation method and application thereof | |
Li et al. | Near-infrared absorbing aza-BODIPYs with 1, 7-di-tert-butyl groups by low-barrier rotation for photothermal application | |
Dang et al. | Double pH-sensitive nanotheranostics of polypeptide nanoparticle encapsulated BODIPY with both NIR activated fluorescence and enhanced photodynamic therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18907318 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18907318 Country of ref document: EP Kind code of ref document: A1 |